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ABSTRACT 
Regulation of E2F-1 Gene Expression in Human Breast Cancer Cells. 
(May 2005) 
Sharon Khethiwe Ngwenya, B.S., Oakwood College 
Chair of Advisory Committee:  Dr. Stephen Safe 
 
 17β-Estradiol induces E2F-1 gene expression in ZR-75 and MCF-7 
human breast cancer cells.  Analysis of the E2F-1 gene promoter in MCF-7 cells 
previously showed that hormone-induced transactivation required interactions 
between estrogen receptor α (ERα)/Sp1 bound to upstream GC-rich sites and 
NFYA bound to downstream CCAAT sites within the -169 to -54 promoter 
region.  This promoter region was also E2-responsive in ERα-positive ZR-75 
cells; however, further analysis of the promoter showed that cooperative 
ERα/Sp1/NFY interactions were not necessary for hormone-induced 
transactivation in ZR-75 cells.  The upstream GC-rich motifs are activated 
independently by ERα/Sp1 in ZR-75 but not MCF-7 cells, and the downstream 
CCAAT sites were also E2-responsive.  E2 also induced reporter gene activity in 
ZR-75 cells transfected with an expression plasmid containing the yeast GAL4 
DNA binding domain fused to pM-NFYA and a construct containing five tandem 
GAL4 response elements.  Subsequent studies showed that hormonal activation 
of pE2F-1jm1 and pM-NFYA are dependent on non-genomic pathways in which 
E2 activates cAMP/protein kinase A.  Hormone-dependent regulation of E2F-1 
 iv
gene expression in ZR-75 and MCF-7 involves different mechanisms, 
demonstrating the importance of cell context on transactivation pathways, even 
among ER-positive breast cancer cell lines. 
TCDD inhibited ERα-mediated responses in MCF-7 and ZR-75 cells.  E2-
induced E2F-1protein and mRNA levels in MCF-7 and ZR-75 cells and this 
response was inhibited by TCDD.  Constructs containing GC-rich sites alone or 
in combination with the downstream NFY sites were used in transactivation 
studies to investigate the mechanism of inhibitory AhR-ERα crosstalk. Although 
TCDD inhibited E2-induced mRNA, protein and reporter gene actitivity, it was 
not possible to determine if the inhibitory response was due to limiting ERα 
protein levels due to proteasome degradation since proteaome inhibitors alone 
blocke hormone-dependent responses.  TCDD also inhibited the cAMP/PKA 
pathway by inhibiting adenyl cyclase activity.  In Drosophila SL-2 cells 
cotransfected with the GC-rich -169 to -54 region, ERα  and Sp1 plasmids E2 
induced transactivation in cells cotransfected with AhR/Arnt expression plasmids 
suggesting that the AhR complex suppressed ERα/Sp1 action.  These results 
demonstrate that TCDD inhibits E2-dependent activation of both non-genomic 
and genomic pathways of ER-mediated E2F-1 gene expression. 
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1 
This dissertation follows the style and format of Cancer Research. 
 
CHAPTER I 
 
INTRODUCTION 
 
1.1 Cancer  
 Cancer is the second leading cause of death in the world.  Cancer 
mortality rates are second only to mortality rates due to heart disease.  The four 
most common cancers are lung, female breast, prostate, and colon cancer.  
These four cancers represent more than half of the cancer diagnoses and 
deaths in the U.S. population.  In 2003, the American Cancer Society predicted 
that over 1.3 million new cases of cancer would be diagnosed and over 500,000 
people would die as a result of cancer.  Although the death rates have declined 
since the mid-1990s, it has been estimated that one of every four deaths is due 
to cancer (1, 2) 
Cancer is a result of an accumulation of mutations that render the cells 
insensitive to growth control (3).  Normal cells proliferate, differentiate, and 
eventually undergo apoptosis in an orderly manner; however, cancer cells are 
deregulated and undergo uncontrolled proliferation that results in tumor 
formation and metastasis. The presence of multiple mutations in cancer cells 
indicates that development of a malignant tumor is a complex process that 
occurs in a stepwise manner.  This process can be described following the 
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classical three phase paradigm of carcinogenesis: initiation, promotion, and 
progression (Fig. 1). 
 
  
 
 
 
 
 
 
 
 
 
Fig. 1.  Stepwise malignant progression of human cancer cells (4). 
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acquired one or more mutations leading to a partial escape from homeostatic 
control of growth (4).   The genotoxic event initiates alterations in genes involved 
in governing either the fidelity of DNA synthesis, the efficacy of DNA repair, 
genes encoding proteins in the cell cycle, or regulation of apoptosis.  Initiators 
can be biological (point mutations, loss or gain of whole chromosomes, viruses), 
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ultraviolet radiation). At this stage, the mutations are not sufficient for the 
development of cancer and premalignant cells must continue to grow and divide 
in order to form a malignant tumor. 
In normal cells, DNA damage triggers checkpoint pathways that usually 
result in cell cycle arrest allowing the cell enough time to either repair the 
damage or undergo apoptosis when DNA lesions are too extensive.  In at least 
50% of human tumors, the checkpoint arrests are defective due to mutations in 
tumor suppressor genes such as p53 and retinoblastoma (RB) which contribute 
to development of multiple cancers including retinoblastoma, breast and 
colorectal cancer (3).  Therefore, as normal cells undergo apoptosis or DNA 
repair after genotoxic damage, cancer cells bypass these checkpoints and 
continue to proliferate and differentiate.  
The second phase of carcinogenesis, promotion, involves clonal 
expansion of the initiated cell to give rise to a population of initiated cells.  
Promoters induce proliferation of the mutant cells but are not usually 
carcinogenic themselves.  However, in some cases initiators can also be 
promoters of carcinogenesis.  Promoters induce additional genetic alterations 
that lead to genetic instability and higher rates of chromosomal modifications.  
Clonal expansion increases the population of initiated cells that have acquired 
some of the mutations critical for carcinogenesis, thus increasing the probability 
that one of these cells will acquire the further genetic changes required for 
malignant transformation (4).  Usually, an initiated cell will have no effect on the 
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neighboring normal cells, but clonal expansion will facilitate the tumors cells 
ability to continue growing and dividing so that it can take over the environment 
surrounding normal cells. 
The accumulation of genetic alterations during initiation and promotion 
subsequently leads to the conversion of the premalignant cells into malignant 
primary tumors.  This is the third phase of carcinogenesis, progression.  At this 
stage, the primary tumor is not invasive or metastatic.  Further accumulation of 
mutations is required to produce new clones that are invasive and metastatic (5).    
The final stage of carcinogenesis is metastasis, a series of steps in which 
the cancer cell leaves the original tumor site and migrates to other parts of the 
body through the bloodstream or lymph system (6, 7).  During metastasis, the 
malignant cells break away from the primary tumor and attach to and degrade 
the proteins that surround the extracellular matrix (ECM) which separates the 
primary tumor from the surrounding tissue.   Once the malignant cells breach the 
ECM, they may spread to lymph nodes near the primary tumor or send signals 
to the surrounding normal host tissues to initiate angiogenesis.  Tumor 
angiogenesis promotes the formation of a new network of blood vessels that 
allow secondary or metastatic tumors to form in other organs and consequently 
starve and displace functional cells so that the organ can no longer perform its 
vital functions (8, 9). 
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1.2 Breast Cancer  
Breast cancer is the most common cancer among women of all races.  
According to the American Cancer Societys publication Cancer Facts & Figures 
2003, it was estimated that approximately 211,300 new cases of invasive and an 
additional 55,700 new cases of non-invasive breast cancer, will have been 
diagnosed in 2003 (2).  Although breast cancer is not common in men, it was 
estimated that 1,300 new cases would be diagnosed in men.  
Breast cancer is the second leading cause of death among women in the 
Western world, second to lung cancer.  And in 2003, approximately 39,800 
women died as a result of breast cancer (10).  The reported incidence of breast 
cancer has risen during recent years due to the increase of mammography 
screening.  However, the mortality rate has decreased dramatically as a result of 
early detection by mammography screenings and improved treatments.  
1.2.1 Mammary Gland Development 
The mammary gland is a structurally dynamic organ varying with age, 
menstrual cycle, and reproductive status.  Development of the mammary organ 
is initiated during the embryonic phase; however, major development occurs 
primarily during the prepubertal phase.  The mammary gland is essentially 
identical in both sexes during the embryonic phase.  The mammary gland first 
appears around day 10 of embryonic development as five pairs of placodes, and 
by day 15 the placodes have formed epithelial buds surrounded by 
mesenchymal cell layers.  These structures further develop into branching 
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network of ducts terminating in end buds through the reciprocal signaling 
between the epithelium, the mammary mesenchyme and the stroma fat pad.   
With the approach of puberty, the mammary gland begins to show signs 
of growth in response to circulating hormones both in the glandular tissue and 
the surrounding stroma.  There is an increase in the glandular size due to the 
growth and division of small bundles of primary and secondary ducts that 
eventually form club shaped structures called terminal end buds (TEB) (11).  
The terminal end buds give rise to new branches called alveolar buds that give 
rise to ducts that cluster around the terminal duct forming the lobule type 1 (Lob 
1) or virginal lobule.  By parturition a small ductal tree has formed (12, 13). 
The normal mammary gland is comprised of two cellular compartments:  
the mesenchymal compartment of fatty stroma which is permeated by blood 
vessels and nerves and the epithelial compartment of ducts and lobules.  The 
normal epithelial compartment is made up of three cell types, the epithelial cells 
which line the ducts, the alveolar cells which line alveoli and the myoepithelial 
cells that are between the epithelial and alveolar cells and the basement 
membrane.  Malignant lesions of rodents and humans usually occur in the 
epithelial cells, specifically the undifferentiated terminal end buds, whereas 
benign lesions usually occur in both epithelial and myoepithelial cells (14).   
 During the period between birth and puberty, development of the 
mammary gland is quiescent.  The only activity during this period would be 
limited ductal elongation into the mammary fat pad.  The changes in the 
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hormonal environment during puberty are the major factors controlling mammary 
development.  In the male, further development is inhibited by production of 
testosterone.  In the female, estrogen acts on the mesenchymal cells to 
stimulate further development. The gland increases in size and the ducts extend 
and branch into the expanding stroma. By adulthood, a simple system of primary 
and secondary ducts has developed and remains in this mature state until 
pregnancy.  With recurrent estrous cycles, some additional budding and 
elongation of the ducts may occur from existing buds to yield a more complex 
gland. 
 Lobule formation in the female mammary gland occurs with 1 to 2 years 
after the onset of menarche.  The breast of an adult woman contains three types 
of lobules, type 1, 2 and 3.  The breast of nulliparous women is mostly 
comprised of undifferentiated structures, such as the terminal end buds and type 
1 lobules, which are sites of preneoplastic lesions which eventually progress into 
invasive carcinoma.  Type 2 lobules are present in moderate numbers during the 
early years but sharply decrease after the age of 23.  In parous women, type 3 
lobules are the predominant structures during pregnancy and until the fourth 
decade of life.  After 40, the number of type 3 lobules decreases. At this stage, 
both nulliparous and parous womens breast are similar in that they both mostly 
have type 1 lobules.  However, it is believed that the type 1 lobules are different 
because in parous women the lobules are fully differentiated and are therefore 
less susceptible for development of malignant tumors (12, 15). 
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During pregnancy the mammary gland experiences the greatest and most 
rapid phase of proliferation.  The phase is driven by the hormones 17β-estradiol 
(E2), progesterone (P), and prolactin (Prl).  Estrogen exerts its effects mainly on 
the ductal system during the first trimester.  Progesterone promotes alveolar 
development during the second and third trimester.  At parturition, there is a 
drop in estrogen and progesterone blood levels.  During this phase, there is an 
increase in the levels of prolactin, released from the anterior pituitary in 
response to a suckling stimulus from the infant.  As a result, large volumes of 
milk are produced and lactation continues until the suckling period ends.  At that 
time, epithelial cells are lost due to apoptosis and mammary glands are reduced 
in size and return to a resting phase. 
1.2.2 Breast Cancer Risk Factors 
1.2.2.1 Hormonal Factors 
 
There are a number of risk factors that lead to development of breast 
cancer.  Among the key factors are the role of inherited genetic susceptibility, 
environmental effects, behavioral patterns and exposure to endogenous and 
exogenous hormones (Fig. 2). Most of these factors affect the levels of 
circulating estrogens.  Estrogen causes proliferation of both normal and 
malignant cells and this mitogenic activity contributes to the role of estrogens in 
initiation and promotion of carcinogenesis.  The role of estrogen as an initiator is 
controversial.  Results from the Ames Salmonella/ microsome direct plate 
incorporation assay suggest that estrogen is not genotoxic and is therefore not a 
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mutagen (16).  Furthermore, human data have failed to correlate high estrogen 
exposure during the time when breast cancer is most likely to be initiated, i.e. 
early adulthood and reproductive years, and increased breast cancer risk (17).  
However, other studies have reported that estrogens are able to induce direct 
and indirect free radical-mediated DNA damage, genetic instability, and 
mutations in cells in culture and in vivo, supporting the role of estrogen as an 
initiator (18).  What is clear is that estrogen is a promoter that causes 
proliferation of malignant cells that leads to an accumulation of DNA adducts in a 
population of initiated cells that eventually progress to form primary tumors. 
 
 
 
 
 
 
 
 
 
 
Fig. 2.  The effects of circulating estrogen levels on breast cancer risk. 
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1.2.2.2 Inherited Genetic Risk Factors 
 
Inherited genetic susceptibility can be attributed to about 5-10% of all 
breast cancer cases (19, 20).  Currently, there are three known genes that when 
inherited in a mutated form, can confer very high lifetime risks for developing 
breast cancer.  These genes are p53, BRCA1 and BRCA2.  
Germ-line mutations of BRCA1 (chromosome 17q21) and BRCA2 genes 
(chromosome 13q12) account for approximately 40% of inherited breast cancer 
cases (21, 22).     It is estimated that in families that have mutations in BRCA1 or 
BRCA2, the cumulative risk of developing breast cancer is 71% up to the age of 
70, which corresponds to a 10- to 20 fold increased risk compared to women 
who do not have these familial gene mutations (23).  Female family members 
who inherit altered forms of one of these three tumor suppressor genes are at 
high risk of developing early-onset, frequently bilateral breast cancer (Fig. 2).  
They are also highly susceptible to other malignancies such as ovarian cancer.   
The majority of inherited breast and ovarian cancer cases are the results of 
mutations in BRCA1, with 20 percent of the cases resulting from BRCA2 
mutations (24).   
BRCA1 protein is expressed in a wide variety of tissues, including the 
breast.  Most of the expression is in tissues containing rapidly proliferating cells 
that are also involved in differentiation.  In rodents, BRCA1 is highly expressed 
during embryogenesis and switches to a more tissue-specific pattern after birth.  
BRCA1 mRNA expression in mammary epithelial cells exhibits a cell cycle-
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dependent pattern.  Expression of BRCA1 mRNA was low in cells arrested in G0 
or early G1 and at the highest during the G1-S phase transition of the cell cycle. 
These data indicate that the expression pattern in BRCA1 is tightly linked to the 
regulation of cellular proliferation.  BRCA1 is also involved in cell differentiation.  
Rajan et.al have also shown that BRCA1 mRNA levels are high in post-confluent 
HC11 mammary epithelial cells during differentiation (25).  BRCA1 also plays an 
important role in repairing oxidative DNA damage.  BRCA1 has been shown to 
interact with RAD51, a protein that is involved in DNA recombination and repair.  
BRCA1 also interacts with the tumor suppressor p53, supporting the idea that 
BRCA1 is involved in DNA repair (26). 
BRCA2 has an important role in maintaining chromosomal stability 
through its participation in DNA recombination and repair.  BRCA2 protein is 
expressed in the same tissues and cell types as BRCA1.  Immunoprecipitation 
data has shown a physical interaction of BRCA2 with BRCA1 (27). Like BRCA1, 
BRCA2 also interacts with RAD51 and other proteins that are involved in DNA 
repair and recombination (28).  The involvement of BRCA2 with RAD51 
indicates an involvement in the repair of double stranded DNA breaks.  Other 
studies have also shown the BRCA1 is phosphorylated as a result of DNA 
damage.  The phosphorylation of BRCA1 is mediated by a protein kinase called 
ATM (ataxia-telangiectasia), which also controls the phosphorylation of other 
proteins involved in double strand breaks.  Hyperphosphorylated BRCA1 co-
localizes with BRCA2 and RAD51 proteins in nuclear foci during the S-phase of 
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the cell cycle.  ATM is found in a nuclear complex with BRCA1 and 
phosphorylates BRCA1 after gamma-radiation induced DNA damage.  
Phosphorylated BRCA1 then activates homologous recombination with the 
cooperation of BRCA2, RAD51, and other DNA repair proteins (29).  In contrast 
to BRCA1, the role of BRCA2 protein is still not very clear.  Co-
immunoprecipitation of BRCA2 with P/CAF, a transcription co-activator with 
histone acetylase activity, indicates another role for this protein as a transcription 
factor (30).   
There are other gene variants that may impact susceptibility to breast 
cancer such as inherited mutations of the p53 tumor suppressor, ataxia-
telangiectasia and PTEN genes.  p53 has the ability to recognize, bind and 
repair damaged DNA, and induce cell cycle arrest and apoptosis. Germ-line and 
somatic mutations of the p53 gene lead to the development of Li-Fraumeni 
syndrome, a rare autosomal dominant syndrome in which patients are 
predisposed to cancer (24, 31).  This syndrome only accounts for less than 1% 
of the breast cancer cases.   
Heterozygous carriers of mutations of the ataxia-telangiectasia (ATM) 
gene have been shown to be at a five-fold increased risk of breast cancer.  ATM 
is a protein kinase that phosphorylates BRCA1, activating its DNA repair 
response upon DNA damage.  Ataxia telangiectasia is a disease characterized 
by cerebral ataxia and defects of the immune system.  Homozygous ATM 
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mutation carriers develop non-Hodgkin lymphoma at an incidence of almost 
100% (32).    
Mutations in the PTEN (phosphatase and tensin homolog) gene result in 
the Cowden syndrome.  Carriers of mutations of this protein tyrosine 
phosphatase tumor suppressor gene have a risk for breast cancer and additional 
tumors such as follicle-cell carcinoma, thyroid and ovarian cancer, as well as 
polyps and cancers of the gastrointestinal tract.  Female breast cancer is seen in 
20-30% of the mutation carriers.  However, the frequency of these inherited 
mutations is low among the general population, suggesting the role of other 
modifiable non-genetic factors such as environmental, behavioral and hormonal 
risk factors.  
There is evidence that high levels of circulating estrogen increase the 
breast cancer risks in carriers of mutations in BRCA1/2, p53 and other tumor 
suppressor genes (17).  This is due to the proliferative effect of estrogen.  The 
mutated tumor suppressor genes allow damaged cells to escape DNA repair, 
apoptosis or cellular arrest, and promotion by estrogen leads to an increase in 
the population of initiated precancerous cells (Fig. 2).   
1.2.2.3 Environmental Risk Factors 
 
Breast cancer incidence rates in the United States are among the highest 
in the world and rates in Western industrialized countries are up to fivefold 
higher than rates in Africa and Asia (33).  Additionally, second or third 
generation American daughters of women who migrate from the low-incidence 
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countries to countries of high incidence acquire the breast cancer risk prevailing 
in the new country (34).  This suggests that environmental effects and lifestyle 
choices are major determinants in the development of breast cancer.   
The increasing incidence of breast cancer and its geographical variations 
has brought greater attention to the role that the environment plays in the 
etiology of breast cancer.  It is now believed that breast cancer is the result of a 
complex interaction of internally and externally introduced factors.  The external 
factors include environmental chemicals that have been called endocrine 
disruptors, chemicals that interfere with the functions of the endocrine system by 
mimicking a hormone, blocking the effects of the hormone, or by stimulating or 
inhibiting the production or transport of hormones.  Endocrine disruptors are 
mainly found in industrial settings rather than the household environments that 
women experience everyday.  However, some of these chemicals have been 
found in small amounts in some households. 
Organochlorines are a group of synthetic chemicals that were 
components of pesticides or industrial products.  The most abundant of these 
contaminants are the pesticide dichlorodiphenyltrichloroethane (DDT) and the 
polychlorinated biphenyls (PCB) which were used in the US from 1945 until they 
were banned in 1972 (35).  Dioxins are also organochlorines that were found as 
contaminants in herbicides.  Dioxin is the general name given to 210 organic 
compounds containing carbon, oxygen and hydrogen with one to eight chlorine 
atoms. Only 17 of the 210 dioxins are known to be toxic. Dioxins can be created 
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naturally in trace quantities (e.g. volcanoes). They can also be created as 
unwanted by-products in numerous combustion processes (e.g. forest fires, 
cigarettes, bonfires, car engines etc.), in metal smelting and recycling processes 
and in the manufacture of a few chlorine-containing chemicals. These chemicals 
are known to have estrogenic and antiestrogenic activity, which may be 
important in increasing or decreasing susceptibility to breast cancer (36).  
Chemicals in this group may also reduce cell-mediated immune functions, which 
would subsequently increase susceptibility to breast cancer (37).  In 1993, Wolff 
and colleagues investigated the role of organochlorines in breast cancer (38).  
They found a two to four-fold increase in the occurrence of breast cancer among 
women with the highest serum levels of dichlorodiphenyldichloroethylene (DDE) 
a metabolite of DDT, and PCBs compared to those with the lowest levels.  
However, since the publication of this study, there have been several reports 
using larger numbers of patients/controls showing levels of PCBs and DDE were 
not higher in breast cancer patients compared to controls ruling out the 
causative effect of organochlorines (39-41).   
Exposure to metals has also been associated with breast cancer risk.  In 
MCF-7 breast cancer cells, divalent cadmium, copper, cobalt and other metals 
activated responses mediated by the estrogen receptor α (ERα) (39).  It was 
found that this activation was more potent than that of phytoestrogens, most 
environmental estrogenic chemicals of concern, and the selective estrogen 
receptor modulators being used to treat breast cancer.  However, ongoing 
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studies in this laboratory suggest that metal ions may only be weakly estrogenic 
(42, 43). The most well established environmental risk factor is ionizing 
radiation.  It has been shown in laboratory animals as well as humans that 
relatively high doses of ionizing radiation increase the rates of breast cancer 
susceptibility.  The most convincing human evidence comes from studies on 
survivors of the atomic bomb blast in Hiroshima and Nagasaki who were 
exposed to gamma radiation (39).  Women who survived the atomic blasts had a 
1.4 to 2.2-fold increased risk for developing breast cancer.  Furthermore, studies 
of adults who survived childhood cancer through radiation treatment indicated 
that breast cancer was the most common second malignancy regardless of 
gender.    
1.2.2.4 Behavioral and Lifestyle Risk Factors 
 
Although rates of breast cancer vary widely by geographic areas, only a 
small component of these differences is due to genetics or exposures to 
environmental chemicals.  It is likely that differences in lifestyle choices and 
health behaviors constitute the major risk factors for breast cancer.  Lifestyle and 
health factors are usually non-genetic risk factors that can be modified and these 
include obesity, diet, reproductive factors and exogenous use of estrogens.   
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Obesity and a sedentary lifestyle account for an estimated 25% of breast 
cancer cases worldwide.  In a study conducted by the American Cancer Society, 
it was found that the risk of breast cancer mortality significantly increased with 
increasing levels of obesity (44).  Some studies have linked high-fat intake with 
an increase in breast cancer risk while other studies show no correlations 
between a high-fat diet and breast cancer risk (17, 45, 46). Both human and 
animal studies indicate that a high-fat diet may increase the estrogen receptor 
content in breast tissue. A high-fat diet may also increase the amount of adipose 
tissue in the body.  Adipose tissue produces estrogen through the aromatization 
of androgens to estrogens (47, 48).  Estrogen produced from adipose tissue is 
the main source of estrogen for postmenopausal women.  Overweight and 
obese postmenopausal women have higher levels of estrogen than their leaner 
counterparts (49, 50).  They also have higher insulin levels, which promotes 
cancer cell growth.  Regular exercise has been shown to reduce the 
concentration of insulin in the bloodstream (51).  Therefore, higher circulating 
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Fig. 3.  Structural similarity exists between estradiol (an estrogen), raloxifene (a 
SERM) and genistein (a phytoestrogen). 
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concentrations of the hormones estrogen and insulin in overweight and obese 
postmenopausal women would explain the increased risk for breast cancer. 
Epidemiological and experimental studies suggest that a diet rich in 
phytoestrogens may have beneficial effects on health (52).  Phytoestrogens are 
non-steroidal plant-derived compounds that possess weak estrogenic effects.  
The chemical structure of genistein, an isoflavone derived from soy products, is 
similar to that of estrogen and raloxifene, a selective estrogen receptor 
modulator (SERM) (Fig. 3) (53).  The structure similarity allows the 
phytoestrogens to compete for the estrogen receptor.  Since phytoestrogens are 
generally weaker than endogenous steroidal estrogens, it has been suggested 
that their competition for the estrogen receptor would be antagonistic.  Asian 
populations exhibit a decreased risk of estrogen-related diseases such as 
cardiovascular disease, menopausal symptoms, postmenopausal osteoporosis, 
and breast cancer.  Protection from these conditions may be a result of a diet 
high in phytoestrogens due to the high consumption of soy products (52).  
Generally, population studies in Asian countries such as Japan and China, as 
well as the United States indicate that phytoestrogens have a protective effect 
against breast cancer and other estrogen-mediated conditions (41).  However, 
there are some concerns that estrogenic properties of phytoestrogens, although 
weak, can be detrimental to women who are at high risk or have breast cancer 
(54, 55). 
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1.2.2.5 Endogenous and Exogenous Estrogens 
 
The role of endogenous and exogenous estrogens is the strongest and 
most consistent risk factor associated with breast cancer.  A womans 
reproductive history plays a key role in determining her exposure to endogenous 
estrogens. Early menarche and late menopause are factors that increase the 
risk of breast cancer, whereas premenopausal bilateral oophorectomy before the 
age of 35, which eliminates ovarian estrogen exposure, decreases the lifetime 
risk by nearly 75% (47).   Studies of the relationship between breast cancer and 
early age at menarche indicated that breast cancer risk is decreased by 10-20% 
for each additional year before the onset of menarche (56).  Early menarche is 
associated with an earlier onset of ovulatory cycles and late menopause 
increases the number of cycles and results in longer exposure to endogenous 
estrogens, which increase cellular proliferation (47, 57).  Increased proliferation 
of the mammary epithelium can enhance promotion of the carcinogenic process.  
Cancer initiation requires the interaction of a carcinogen with an undifferentiated 
and highly proliferating mammary epithelium.  Therefore longer exposure to 
ovarian hormones results in increased probability for carcinogens to interact with 
the proliferating mammary epithelium. 
Parity and the age at first full term pregnancy have been identified as 
protective factors against breast cancer.  Although parous women have a 
decreased risk compared to nulliparous women, it is the age of their first delivery 
that is the most protective (21, 58).  Some reports indicate that multiparity may 
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be protective, however Trichopolous and coworkers showed that the age at first 
birth (before 28 years ) was still the most important factor (59).  In studies that 
investigated the relationship between breast cancer and parity, each full term 
pregnancy led to 10-15% decrease in risk for breast cancer (56).  Full term 
pregnancy leads to differentiation of the mammary gland resulting in the removal 
of a population of highly proliferating cancer-susceptible cells.  Mammary gland 
differentiation involves the interaction of ovarian, pituitary, and placental 
hormones that induce inhibition of cell proliferation (60).  A mammary gland that 
has encountered a full term pregnancy at an early age undergoes differentiation 
that decreases the number of cancer-susceptible cells at an early age, thereby 
decreasing the overall risk of breast cancer. 
Since the 1960s, female sex hormones have been used as 
contraceptives.  These hormonal contraceptives are usually composed of 
synthetic or natural versions of estrogens and progestins.  Theoretically, the use 
of exogenous hormones over the course of a womans life could increase the 
risk of breast cancer by increasing the opportunity for initiation, or by promoting 
genotoxic events occurring at an early age.  However, results from studies of the 
effects of oral contraceptives (OC) on breast cancer risks have produced 
controversial results.  European studies from the United Kingdom and the 
Netherlands have reported an increased risk associated with OC use in women 
diagnosed before the age of 36 (61, 62).  Other studies also indicate that early 
use of OCs increases the risk of breast cancer.  However, most of the results 
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vary with parity and age at diagnosis (63).  Most studies have reported that there 
is no significant association between OC use and breast cancer risk (64, 65).  In 
many cases, women who used OCs and were diagnosed with breast cancer had 
significantly fewer full term pregnancies and were older at the first term of 
pregnancy (66).  Reproductive behavior is more likely to be the cause of the 
increased risk rather than use of OCs. 
There is an increasing concern that the use of hormonal replacement 
therapy (HRT) may be a risk factor for breast cancer.  HRT is the peri- and 
postmenopausal use of sex hormones, mainly estrogen alone or in combination 
with progesterone, to relieve climatic symptoms associated with menopause 
(67).  Breast cancer is more frequently diagnosed in women who have a history 
of prolonged use of HRT.   HRT may have a potential role in the activation of 
dormant cancer cells rather than induction of malignant transformation (68).  
Results for studies of the risk of HRT and breast cancer are controversial.  While 
most studies indicated that women who use HRT are not at a higher risk of 
breast cancer than their counterparts who do not use HRT, the use of HRT is 
generally not recommended for women who are at high risk for breast cancer 
(69, 70). 
1.3 Estrogen 
 17β-Estradiol (E2) is the most abundant naturally occurring estrogen in 
the body followed by estrone (E1) and estriol (E3).  Estradiol is mainly secreted 
by the ovaries and is the predominant estrogen during the premenopausal 
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period.  Estrone is the main estrogen after menopause and is synthesized in the 
adipose tissue from adrenal dehydroepianadrosterone.  Estriol is the principle 
estrogen formed during pregnancy, and is produced primarily in the placenta 
(71). 
1.3.1 Estrogen Synthesis 
 Bioactive estrogens are synthesized from inactive steroids as well as 
androgenic precursors (androstenedione or testosterone) and estrone sulfates 
through aromatization and hydrolysis of the sulfate group respectively (Fig. 4).  
Aromatase (also known as CYP19), a member of the cytochrome p450 
superfamily of genes, is the key enzyme in estrogen biosynthesis.  Aromatase 
catalyzes the aromatization of the androgen androstenedione, an inactive 
androgen secreted from the adrenal cortex or gonads, to estrone (72). Over 70% 
of breast carcinoma specimens express aromatase activity.  Most of the activity 
was detected in stromal cells and adipocytes adjacent to the carcinoma, 
indicating a correlation between aromatase expression with carcinoma invasion.  
Subsequently, aromatase inhibitors have been used as treatment for breast 
cancer (73). 
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Fig.. 4.  Estrogen biosynthesis in human breast carcinoma tissue (74). 
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1 (Fig. 4) (75).  Both estradiol and estrone can be hydroxylated by 16α-
hydroxylase (Fig. 4) (74). 
1.3.2 Estrogen Metabolism 
 There are several hypotheses concerning the mechanisms whereby 
estrogens cause breast cancer (Fig. 5).  The first and most commonly held 
hypothesis is that estrogens bind to the estrogen receptor and stimulate the 
transcription of genes involved in cell proliferation and differentiation.  The 
second and more controversial hypothesis is that estradiol forms genotoxic 
metabolites that directly damage DNA.  There has been some data supporting 
the genotoxic metabolism hypothesis (76, 77).  However, most of these data are 
either not repeatable or provide indirect evidence and do not completely rule out 
the classical estrogen receptor hypothesis. 
 In the genotoxic metabolism hypothesis (Fig. 5), estradiol is hydrolyzed to 
4-OH-estradiol by CYP1B1, a member of the cytochrome P450 superfamily.  
Breast cancer tissue exhibits significantly higher levels of 4-OH-estradiol and 
CYP1B1 than normal breast tissue (78, 79).  4-OH-Estradiol is then converted to 
estradiol-3,4-quinone, which can bind guanine or adenine.  4-OH-estradiol-
guanine or 4-OH-estradiol adenine is released from the DNA and leaves 
depurinated DNA.  At this point, DNA repair occurs in normal cells, however, in  
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Fig. 5.  Mechanisms of E2-induced mammary carcinogenesis (76, 77).  
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cases where DNA repair is faulty, point mutations which serve as potential 
initiators of neoplastic transformation are formed (80).  This pathway is 
hypothesized to act additively or synergistically with the estrogen receptor 
pathway to induce breast cancer. 
 In another form of the genotoxic hypothesis, the quinone metabolites of 
estrogen can also cause oxidative damage to lipids and DNA through redox 
cycling processes that produce reactive oxygen species (ROS) where oxygen is 
partially reduced to form a free radical that forms DNA adducts with all bases of 
DNA instead of only the guanines (Fig. 5).  If a cell has antioxidant enzymes and 
radical scavengers which mitigate the toxicity of the free radicals, DNA damage 
can be repaired. However in cases were there is excessive generation of ROS, 
this could lead to disruption of cellular redox homeostasis and, as a 
consequence, an alteration of transcription factor function, causing inappropriate 
alterations in the regulation of gene expression (81). 
1.4 Transcription 
1.4.1 Chromatin Structure 
The human genome is comprised of approximately three billion base 
pairs of deoxyribonucleic acid (DNA) that express over 30,000 genes.  DNA is 
contained in a compact area and is seen as a mass of chromatin in eukaryotic 
nuclei during interphase.  The packaging of chromatin changes during the cell 
cycle; at the time of all division, mitosis or meosis, the genetic material becomes 
even more tightly packaged into individual chromosomes.  Chromatin has a 
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compact organization in which most DNA sequences are structurally 
inaccessible and functionally inactive.  Within this mass are the majority of active 
sequences required for transcriptional activation of specific genes.   
There are several hierarchies in the organization of chromatin.  The first 
level is the winding of DNA into the bead-like particles, forming a 10 nm fiber 
that is a component of euchromatin, heterochromatin, and chromosomes.  At 
this level, a continuous duplex thread of DNA runs through a series of particles 
called nucleosomes.  The nucleosome contains ~200 bp of DNA associated with 
a histone octamer that consists of two copies each of the core histones. The 
second level of organization is the coiling of the nucleosome into a helical array 
to constitute the ~30 nm fiber that is found in both interphase chromatin and 
mitotic chromosomes. The third level of organization is the packaging of the fiber 
itself into chromosomes.   
In order for DNA to be synthesized or transcribed, the structure of 
chromatin must be unfolded in order to gain access to the coding sequences.  
Transcription factors bind to the nucleosome and subsequently recruit enzymatic 
activities which will alter the chromatin in a way that permits the recruitment of 
the basal transcription machinery and other factors (Fig. 6).  The unfolding is 
made possible through acetylation of histone core proteins by histone 
acetyltransferase enzymes (82).  Histone acetylation causes direct physical 
changes in the secondary structure of the nucleosome by neutralizing the 
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positive charge of the scaffolding proteins (83).  Changes in the nucleosomes 
secondary structure modify protein-protein and protein-DNA interactions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.  Chromatin modification by histone acetyl transferase.  GTF - general 
transcription factors.  RNAPII  RNA polymerase II. 
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1.4.2 Transcription Initiation 
 Activation of genes to express their encoded proteins is dependent 
on both transcription and translation.  Transcriptional regulation of gene 
expression can be divided into three distinct steps, namely, initiation, elongation, 
and termination.  In order for RNA polymerase II (RNAP II) to transcribe a gene, 
it needs to be recruited to the promoter, assembled with general transcription 
factors (GTFs), and then initiate the transcript.  DNA serves as a template for the 
synthesis of ribonucleic acid (RNA) much as it does for its own replication.  
Protein-coding genes have a number of sites that are important for gene 
expression.  The transcription start site is where a molecule of RNA polymerase 
binds to begin transcription.  There are three types of RNA polymerase.  RNA 
polymerase I transcribes 28S, 18S, and 5.8S ribosomal RNA (rRNA) that is used 
in the building of ribosomes, the machinery for synthesizing proteins by 
translating messenger RNA (mRNA).  RNA polymerase II (RNAP II) is found in 
the nucleus and is comprised of a complex of 12 different proteins.  RNAP II is 
responsible for synthesizing mRNA from the DNA template.  RNA polymerase III 
is located outside the nucleolus, transcribing 5S rRNA (a part of the large 
subunit of the ribosome), U6 snRNA, some small RNA, and all tRNA genes that 
carry amino acids to the growing chain of RNA (84). 
Transcription is initiated by RNAP II at the proximal promoter, the region 
within the immediate vicinity of the transcriptional start site (85).  The promoter 
can be divided into core and regulatory elements.  The core elements are the 
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sites for assembly of the preinitiation complex.  The core elements can include 
the TATA box and an initiator sequence (86).  These elements may be found 
together or separately on gene promoters.  The regulatory elements include 
enhancers and silencers that allow transcription to be regulated from a distance. 
The TATA box is a sequence of seven bases (TATAAA) upstream of the 
start site on the 5 side of the gene.  It has been observed that although TATAAA 
is the consensus sequence, variations of this sequence are also functional (85, 
86). The TATA box is usually located 25 to 30 bp from the start site.  During 
transcription, the TATA box is bound by a large complex of over 50 different 
protein transcription factors that form the preinitiation complex in a stepwise 
manner (Fig. 7) (84). At first, the general transcription factor IID (TFIID) which is 
a complex of TATA-binding protein (TBP) and eight other protein factors known 
as TBP-associated factors (TAFs) which bind to TBP and each other but not to 
DNA, recognizes and binds to the TATA box. TFIIA then binds TFIID to form a 
D-A complex that is thought to stabilize the TFIID-DNA interactions. TFIIA 
binding is followed by TFIIB, the only member of this complex that binds both 
DNA and RNAP II.  Finally, TFIIF recruits RNAP II to the promoter and 
preinitiation complex is formed after the addition of TFIIE, and TFIIH. At this 
point, some of the factors leave the preinitiation complex, and promoter. 
 
 
 
 
  
32
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 7.  Formation of the preinitiation complex (82). 
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clearance occurs as contact between the promoter and RNAP II is broken, and 
RNAP II initiates transcription  (87).   
Initiator elements (Inr) encompass the transcriptional start site.  The 
location of the Inr sites can be determined by spacing from the TATA box (85).   
However, Inr can also be found in TATA-less promoters.  In the case of TATA-
less promoters, Inr acts as the site for the assembly of the preinitiation complex 
and there is evidence that Inr is bound by TFIID in a sequence specific manner 
(86).  More specifically, some of the TBP-associated factors (TAFs) in the TFIID 
complex are responsible for interaction of TFIID with Inr.  RNAP II is also able to 
recognize and bind Inr and mediate transcription in an Inr-dependent manner.  
Therefore, TFIID and RNAP II can be recruited to the promoter in a TATA-
dependent and TATA-independent manner. 
Enhancers and silencers are cis-acting DNA sequences that increase and 
decrease transcriptional rates, respectively. Some transcription factors bind to 
enhancer regions of the DNA that are thousands of base pair away from the 
gene they control (88, 89).  Enhancers can be located upstream, downstream, or 
even within the gene they control.  Most enhancer binding proteins interact with 
their cognate DNA binding sites and also bind transcription factors assembled at 
a specific gene promoter (90).  These sites cause the enhancer binding proteins 
to draw the DNA into a loop that allows interaction with proteins assembled at 
the promoter region and thereby facilitate target gene expression (Fig. 8).   
  
34
 
 
 
 
 
 
 
Fig. 8.  DNA bound with transcription factors. 
 
 
Silencers are control regions of DNA that, like enhancers, may be located 
thousands of base pairs away from the gene they control (85).  However, when 
transcription factors bind to them, target gene expression is repressed.   
TFIIH has DNA helicase activity that is responsible for unwinding DNA in 
order to allow RNAP II to transcribe DNA into mRNA (91). TFIIH is recruited to 
the DNA and the resulting RNAP II and transcription factor complex induces the 
12-15 bases of the DNA double helix to separate forming a transcription bubble 
that allows RNAP II to proceed down one strand reading the DNA message in a 
3 to 5 direction (92).  In eukaryotes, this requires the removal of the 
nucleosomes in front of the advancing RNAP II.  A complex of proteins is 
responsible for the removal of the nucleosome.  The same complex is also 
responsible for replacing nucleosomes after the DNA has been transcribed and 
RNAP II has moved on. 
TATA
DNA
DNA sequence-
specific 
transcription 
factors
Enhancer/silencer
Exons
TRANSCRIPTIONTBPTFIIA
TFIIF RNAPII
TFIIB TFIIE
TFIIJ TFIIH
  
35
As the RNA polymerase travels along the DNA strand, it assembles 
ribonucleotides into a strand of RNA.  Each ribonucleotide is inserted into the 
growing RNA strand and RNA is synthesized in a 5 to 3 direction.  As each 
nucleoside triphosphate is brought in to add to the 3 end of the growing strand, 
the two terminal phosphates are removed and a phosphodiester bond is formed 
(91).  After the formation of the phosphodiester bond, two to three unstable 
bases are synthesized and abortively released by RNAP II.  The abortion of two 
to three base transcripts is followed by the generation of longer transcripts of 
approximately 11-15 bases and the closing of the opened upstream DNA region.  
The downstream part of the transcription bubble can then continue to expand to 
allow the procession of RNAP II with the concomitant closure of the upstream 
region.   
Transcriptional termination occurs when RNAP II encounters a 
termination signal on the DNA.  Unlike initiation, termination does not always 
occur at the same bases, but at a zone downstream that contains loosely 
defined terminator sequences.  When the terminator sequence is encountered, 
RNAP II and its transcript are released from the DNA and RNAP II is recycled in 
order to participate in another round of transcription (92).   
1.4.3 Transcription Factor Sp1 
Specificity protein 1 (Sp1) is a member of the Sp/KLF (Krüpple-like factor) 
family of proteins that have been shown to interact with GC-rich promoter 
elements.  Dynan and Tjian first identified Sp1 in 1983 by its ability to selectively 
  
36
bind and activate transcription of the viral SV40 promoter (93).  Sp/KLF proteins 
bind to a GC-rich decanucleotide sequence known as the GC-box with a 
consensus sequence of GGGCGG.  Subsequent studies revealed that multiple 
genes that contain GC-boxes are activated by Sp1 and related Sp proteins, and 
these include genes such as thymidine kinase (94, 95), insulin-like growth factor-
1 receptor (96), dihydrofolate reductase (DHFR) (97), growth hormone (GH) 
receptor (98), and alcohol dehydrogenase 5 (ADH5) (99).    Most GC-boxes are 
located near binding sites for other transcription factors, and the Sp/KLF proteins 
often act in conjunction with other transcription factors to modulate transcription.   
Kadonaga et.al  cloned Sp1 cDNA from HeLa cell RNA and determined 
the various functional domains using in vitro and whole cell assays (100).  The 
structural domains of members of the Sp/KLF family include the N-terminal A 
domain and the central B domain which contains a glutamine-rich (Q-rich) 
activation domain flanked by highly conserved serine/threonine-rich regions (Fig. 
9).  The most highly conserved region is the DNA-binding region which contains 
three characteristic zinc finger binding motifs encompassed in the C and D 
domains in the C-terminal region.   
 Other Sp/KLF members that bind the GC-box include Sp2, Sp3, and Sp4 
which are structurally related to each other and Sp1.  Sp2 and Sp3 proteins also 
bind GT-rich elements.  Sp1, Sp3, and Sp4 are the Sp proteins with the highest 
homology containing the characteristic three zinc finger binding motifs, similar 
activation domains and other structural motifs (101, 102).  Other members of the 
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Sp/KLF family (Sp5, Sp6, Sp7, Sp8, and the Krüpple-like factors) differ from the 
first four members because they are generally of lower molecular weight and do 
not contain the Q-rich activation domain in the N-terminal region. 
 
 
   
 
 
 
 
 
 
 
 
 
Fig. 9.  Members of the Sp family of transcription factors (100). 
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survived until day 9.5 of gestation, and exhibited a broad range of phenotypic 
abnormalities (110).  They also looked at housekeeping, cell cycle-regulated, 
and tissue restricted genes and found there were no differences in Sp1 
expression.  Moreover, the CpG islands remained methylated, indicating that 
Sp1 is essential for preventing methylation of CpG islands (111).  This data 
indicates that Sp1 expression is essential for cell growth and differentiation.  In 
most cases when Sp1 is knocked out, it is assumed that other members of the 
Sp family such as Sp3 and Sp4 compensate in part for the loss of Sp1 activity in 
transcriptional regulation of certain genes. 
 Sp1-dependent activation of gene expression requires interaction with a 
coactivator complex named CRSP (cofactors required for activation of Sp1).  
CRSP is a multisubunit complex of six to eight polypeptides that has domains 
similar to previously characterized polypeptides (112, 113).  CRSP is also 
involved in Sp1-mediated activation of GC-rich genes with TATA boxes or 
initiator sequences and plays a role in the interactions with proteins of the RNA 
polymerase preinitiation complex.  
 Sp1 can directly interact with the TBP (114) and with TATA-binding 
protein associated factors (TAFs) such as TAF130 (115) and TAF110 (116, 117) 
and other members of the preinitiation complex though the glutamine (Q)-rich 
activation domains A and B and with TAF55 through the C-terminal domain 
(118).  In the case of TATA-less promoters, there have to be multiple GC-boxes 
for Sp1 to activate transcription.  Insulin-like growth factor-binding protein-2 
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(IGFBP-2) gene has a TATA-less promoter and transactivation of the IGFBP-2 
promoter can be achieved as long as the three GC-boxes in the minimal 
responsive promoter region remain intact (119).  
Sp1 also interacts with some proteins that are not directly involved in the 
transcription machinery in order to activate or repress transcription.  Most of the 
proteins that functionally interact with Sp1 are sequence-specific transcription 
factors.  These include ubiquitous factors like Oct-1 (120), NF-κB (121, 122), 
and E2F-1 (94, 123).  In the murine thymidine kinase promoter, binding sites for 
Sp1 and E2F are 10 bases pairs apart and interactions between these proteins 
are cooperative.  Sp1 and E2F also interact cooperatively on the dihydrofolate 
reductase (DHFR) and thymidine kinase promoters to activate expression 
synergistically.  In the DFHR promoter, both proteins are required for synergism.  
Sp1 also functionally interacts with GATA-1, an erythroid transcription factor 
(124).  Interactions between GATA-1 and Sp1 activate the erythropoietin 
receptor (EpoR) and chicken α-globin promoters through physical interactions 
mediated through the zinc finger domains on Sp1.  
 In some instances, GC-boxes can also function as transcriptional repressor 
sites as in the case of the human multidrug resistance (MDR1) promoter.  
Through mutational and deletion analysis, Cornwell and Smith showed that the 
transcriptionally active region of the MDR1 promoter was a -122 to +1 region 
relative to the initiation site (125).  This promoter sequence contains two GC-
boxes that are important for transcriptional regulation.  They found that while the 
  
40
-50 GC-box was involved in activation of transcription, the -110 GC-box was 
associated with transcriptional repression.   
Repression through the GC-boxes can occur though Sp1 DNA binding 
competition with other Sp proteins.  In cases where a promoter contains multiple 
GC-boxes Sp3 can bind DNA more stably than in promoters with only one GC-
box (126).  Sp3 binds the GC-boxes as a monomer that slowly forms a complex 
with other proteins.  The resulting Sp3-DNA complex is significantly more stable 
than monomeric Sp3-DNA complexes as well as multimeric Sp1-DNA 
complexes.  In this case Sp3 becomes a repressor by efficiently displacing Sp1, 
and preventing Sp1-dependent transactivation. 
In other cases, transcriptional repression through Sp1 can occur through 
protein-protein interactions with other transcription factors (127).  For example, 
FBI-1 is a transcription factor that contains the POZ domain, a protein-protein 
interaction motif.  FBI-1 was shown to physically interact with the zinc finger 
DNA-binding domain of Sp1 and prevent it from binding the ADH/FDH promoter 
and subsequently repressing transcription.  The interaction of FBI-1 with the zinc 
finger domain of Sp1 is thought to interfere with the ability for Sp1 to recognize 
the GC-box. 
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1.5 Estrogen Receptors 
1.5.1 Nuclear Hormone Receptors 
 The estrogen receptor (ER) is overexpressed in over half of all breast 
cancer cases, and around 70% of these cases respond to antiestrogen therapy 
(128).  The ER is a member of the nuclear hormone receptor superfamily.  
Nuclear receptors (NR) are sequence-specific DNA binding transcription factors 
that comprise a superfamily that includes over 300 known members.  Many 
nuclear receptors bind low molecular weight lipophilic ligands that have the 
ability to readily cross the plasma membrane and enter the cytoplasm and 
nucleus (129).  A subset of these receptors is called steroid hormone receptors, 
a nuclear receptor sub-family that binds specific steroids and related compounds 
and mediates transcription of target genes.  Other NRs bind structurally diverse 
endogenous and/or synthetic ligands and orphan receptors have no known 
ligands.  
The nuclear receptor superfamily can be divided further into subfamilies 
(Table 1) (130).  The first subfamily consists of the thyroid hormone (TR), 
retinoic acid (RAR), vitamin D (VDR) and peroxisome proliferators-activated 
receptors (PPAR), as well as orphan receptors.  The second subfamily is made 
up of the retinoic X receptors (RXR) as well as the receptors involved in eye 
development (TXL and PNR), chicken ovalbumin upstream stimulator (COUP), 
hepatocyte nuclear factor 4 (HNF4), and testis receptors (TR). The third 
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superfamily is comprised of steroid receptors such as the estrogen receptor 
(ER), the progesterone receptor (PR) and related orphan receptors such as the  
 
Table 1.  Mammalian nuclear factor subfamilies (130). 
 
RECEPTOR SUBTYPE DENOMINATION LIGAND 
RESPONSE 
ELEMENT M, D, Ha 
CLASS I 
 
TR 
 
α,β 
 
Thyroid Hormone 
receptor 
Thyroid 
Hormone 
Pal, DR-4, 
IP 
H 
 RAR α,β,γ Retinoic acid 
receptor 
Retinoic acid DR-2, DR-5, 
Pal, IP 
H 
 VDR  Vitamin D 
receptor 
Vitamin D DR-3, IP-9, 
DR-1 
H 
 
 PPAR α,β,γ Peroxisome 
proliferator 
activated 
receptor 
Wy 14,643, 
prostaglandin 
Js, poly 
unsaturated 
fatty acids 
DR-1 H 
 PXR  Pregnane X 
receptor 
Pregnanes, 
C21 steroids 
DR-3 H 
 CAR α,β Constitutive 
androstane 
receptor 
Androstanes DR-5 H 
 LXR α,β Liver X receptor Oxysterols DR-4 H 
 FXR  Farnesoid X 
receptor 
Bile acids DR-4, IR-1 H 
 RevErb α,β Reverse Erb Unknown DR-2, 
Hemisite 
M,D 
 RZR/ROR α,β,γ Retinoid Z 
receptor/retinoid 
acid related 
orphan receptor 
Unknown Hemisite M 
 UR  Ubiquitous 
receptor 
Unknown DR-4 H 
       
CLASS II RXR α,β,γ Retinoic acid 
receptor 
9-cis-retinoic 
acid 
Pal, DR-1 D 
 COUP-TF α,β,γ Chicken 
ovalbumin 
upstream 
promoter 
transcription 
factor 
Unknown Pal, DR-5 D,H 
 HNF-4 α,β,γ Hepatocyte 
nuclear factor 4 
Fatty acyl-CoA 
thioesters 
DR-1, DR-2 D 
 TXL  Tailles-related 
receptor 
Unknown DR-1, 
Hemisite 
M,D 
 PNR  Photoreceptor-
specific nuclear 
receptor 
Unknown DR-1, 
Hemisite 
M,D 
 TR2 α,β Testis receptor Unknown DR-1 to DR-
5 
D,H 
       
CLASS III GR  Glucocorticoid 
receptor 
Glucocorticoids Pal D 
 AR  Androgen 
receptor 
Androgens Pal D 
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Table 1. Continued. 
 
RECEPTOR SUBTYPE DENOMINATION LIGAND 
RESPONSE 
ELEMENT M, D, Ha 
 PR  Progesterone 
receptor 
Progestins Pal D 
 ER α,β Estrogen 
receptor 
Estradiol Pal D 
 ERR α,β,γ Estrogen-related 
receptor 
Unknown Pal, 
Hemisite 
M,D 
       
CLASS IV NGFI-B α,β,γ NGF-induced 
clone B 
Unknown Pal, DR-5 M,D,H 
       
 
CLASS V SF-1/FT-
F1 
α,β Steroidogenic 
factor 1  
Fushi Tarazu 
factor 1 
Oxysterols Hemisite M 
       
CLASS V1 GCNF  Germ cell 
nuclear factor 
Unknown DR-0d  
a Monomer (M), Homodimer (D), Heterodimer (H) 
 
 
 
estrogen related receptor (ERR).  The fourth, fifth, and sixth subfamilies are 
made up of orphan receptors such as NGFI-B, SF-1, and GCNF.   
There are two estrogen receptor isoforms, classical ERα and the recently 
discovered ERβ (131).  ERα and ERβ differ in their tissue distribution.  ERα is 
mainly expressed in the epithelial cells of estrogen target tissues such as the 
uterus, ovaries, and breast tissues (128).  ERβ is expressed in a wider range of 
tissue including those of the central nervous system (CNS), cardiovascular, 
respiratory, gastrointestinal, endocrine, urogenital, musculoskeletal, and 
reproductive systems (132, 133).  ERβ expression in these tissues in not limited 
to the epithelial cells, but can also be detected in nuclei of stomal fibroblasts, 
endothelial cells, and immune infiltrates.   
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In the normal mammary gland and during pregnancy ERβ is highly 
expressed in 70% of the epithelial cells and is the dominant ER since there is 
very little expression of ERα.  Low expression of ERα is most likely due to 
degradation of ERα in response to E2 early during the cell cycle through the 
ubiquitin-mediated degradation pathway (134, 135).  This indicates that 
proliferation in the normal mammary gland and during pregnancy, one of the 
most proliferative phases of breast development, is due to an ERα response to 
E2.  However, ERα must be degraded in order for the cell to progress through 
the cell cycle.   ERα is the dominant receptor expressed in 80% of the epithelial 
cells of malignant mammary tumors (136, 137).  Although both ERα and ERβ 
are expressed in the malignant mammary gland, only ERα is responsive to 
antiestrogen therapy and is therefore the main target for endocrine therapy. In 
most cases, ERα expression in mammary tumors is an indicator of a positive 
prognosis (128, 131, 138).  
1.5.2 Estrogen Receptor Structure 
Members of the nuclear receptor superfamily share a similar structure 
with different regions corresponding to functional domains that can be 
interchanged between related receptors.  The structure includes a variable A/B 
region in the NH2-terminal domain, a C region that contains the DNA-binding 
domain (DBD), a hinge region D, and a conserved E region that consists of the 
ligand-binding domain (LBD) in the COOH-terminal domain.  Some of the  
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Fig. 10.  Domain structure representation of human ERα and ERβ isoforms. 
 
receptors also contain an F region whose function is not well characterized (Fig. 
10). 
The A/B region contains the transcriptional activation function 1 (AF-1) 
domain and is the most variable region of the receptor.  Most receptor isoforms 
differ mainly in the A/B region.  For example, receptor isoforms for the 
progesterone receptor (A and B), thyroid hormone receptor (TRβ1 and TRβ2) as 
well as the retinoic acid receptor (RARα, RARβ, RARγ) have highly homologous 
sequences in their DBDs and LBDs, but differ greatly in their A/B regions (139).  
The AF-1 domain of ERβ exhibits 18% homology with the ERα AF-1 domain 
(Fig. 10) (140).  There is also an 80 amino acid difference between the AF-1 
domain of the two isoforms and the variability of the AF-1 domain generally 
results in functional differences between the receptor isoforms.  These 
differences include lower transcriptional activity of ERβ compared to ERα in 
several cell lines, higher binding affinity of ERβ for phytoestrogens coumestrol 
AF-1 DBD AF-2
1 180 260 301 553 596
A/B C D E F
AF-1 DBD AF-2
1 144 224 254 504 530
18%
hERα
DOMAINS
HOMOLOGY
hERβ
18% 97% 30% 47%
LBD
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and genistein, absence of agonistic activity of the antiestrogen 4-OH-tamoxifen 
on ERβ through ERE sites.  
 Ligand-dependent activation of GC-rich elements though interactions of 
ERα or ERβ with the Sp1 transcription factor was observed only for ERα (139, 
141, 142). In domain swapping experiments, it was shown that substitution of 
the amino-terminal domain of ERβ with that of ERα produced  a chimeric protein 
that had the ERα AF-1 domain and the ERβ AF-2 domain (ERα/β). This 
substitution resulted in improved transactivation of the ERα/β chimera in 
response to E2.  Conversely, substitution of the amino terminal domain of ERα 
with the ERβ amino terminal (ERβ/α) resulted in a chimeric protein that had the 
ERβ AF-1 domain and the ERα AF-2 domain (ERβ/α) that produced decreased 
transactivation.  These results indicate that the AF-1 region of ERα is 
responsible for transactivation though the GC-rich elements. (141, 143).  
The AF-1 domain shows promoter and cell type specificity, indicating that 
it is responsible for modulating the activity of the various receptor isoforms and 
interaction with cell-specific factors to modulate transcription.  It has been shown 
that the AF-1 domain makes physical and functional contacts with general 
transcription factors, coactivators and other transcription factors in order to 
stabilize the preinitiation complex (144-146).   
The AF-1 domain is also responsible for ligand-dependent and 
independent transcriptional activation or repression.  In most cases, activation of 
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nuclear receptors through the AF1 region is due to phosphorylation mediated by 
different kinase signaling pathways.  For ERα, amino acids 41-150 are required 
for AF1 activity and amino acids 91-121 are required for interactions of AF-1 with 
AF2 in LBD.  Serines 118, 104, 167, and 122 are targets for phosphorylation 
through different kinase pathways (MAPK, cyclin A2-CDK2, casein kinase II, and 
protein kinase C (PKC)-δ respectively) in response to estradiol and growth 
factors (147-151).   
 Nuclear receptors regulate gene expression by interacting with specific 
DNA transcription factors that regulate gene expression and by directly binding 
to specific DNA promoter sequences of target genes.  A two-step mechanism of 
action was proposed as early as 1968 based on the observation that there were 
inactive and active states of the receptors (152).  The first step involves binding 
of the ligand to the receptor and the second step involves the binding of the 
receptor to the DNA and consequently regulating transcription.   
The C region contains the DNA binding domain (DBD), and is the most 
conserved region of all the nuclear receptors.  This domain is responsible for 
recognizing and binding specific response elements on the DNA and activating 
expression of the gene of interest.  The DBD of nuclear receptors usually 
contains eight cysteine residues as well as two zinc ions that are required for 
DNA binding.  This domain has two zinc finger domains that are each comprised 
of four cysteines that coordinate tetrahedrially with one zinc ion.  These two zinc 
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finger motifs fold together to form a structure that recognizes and binds DNA 
(Fig.11).   
 The zinc fingers of ERα contain a P box at the base of the first zinc finger 
that is responsible for specific interactions with DNA and contact with the central 
base pairs of the palindromic response element.  The second zinc finger 
contains the D box that is involved in dimerization (153).  The core of the DBD 
contains two α-helices, the recognition helix that binds the major groove of the 
DNA and the helix that spans the C-terminus of the second zinc finger forming a 
right angle with the recognition helix (Fig. 12) (130). ERα and ERβ share very 
similar DBDs (97% similarity) that bind to the same estrogen response element 
(ERE) (140).    
 
 
 
 
 
 
 
Fig. 11. The zinc finger motif of the DNA binding domain of the nuclear 
receptors. 
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Fig. 12.  The DNA binding domain of the estrogen receptor-α. 
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The D region of ERs is comprised of the hinge domain.  The hinge 
domain is not very well conserved among nuclear receptors, with 30% homology 
between ERα and ERβ (140). This region serves as a linker between the DBD 
and LBD.  In most cases, the hinge domain contains the nuclear localization 
signals and residues that determine interactions with corepressors.  The D 
region is involved in the conformation changes of nuclear receptors allowing 
rotation of the DBD upon ligand binding (130).   
Most receptors are inactive when not bound to their ligands.  In the 
absence of ligand, the steroid hormone receptors are sequestered by chaperone 
proteins, such as the heat shock proteins (154).  When the ligands bind the 
ligand binding domain (LBD) within the E region, the nuclear receptor undergoes 
a conformational change that releases the chaperone proteins and facilitates 
interaction with specific DNA sequences.  The LBD is a multifunctional domain 
that harbors the hormone binding site, mediates homo- and heterodimerization, 
and interaction with coactivators and corepressors.  Despite low sequence 
similarity, the three dimensional structures of LBDs are similar for most nuclear 
receptors.  LBDs are formed by 12 conserved α-helical regions numbered HI to 
H12 (130).  The helices are organized in a three-layered anti-parallel sandwich 
structure with a center core layer of three helices that create a ligand binding 
pocket that accommodates the ligand.   This cavity is mainly hydrophobic and is 
buried within the bottom half of the LBD.  An anti-parallel β-sheet closes the 
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ligand pocket on one side and H12 closes another side.  The cavity is 
completely protected from the external environment and buries the ligand in a 
highly hydrophobic environment. 
The ER can form different types of dimers that depend on the bound 
ligand.  The dimerization interface involves helices H8 to H12 interaction with a 
hydrophobic leucine zipper-like interaction zone and hydrophilic contacts (153).  
H11 and H12 helices are important for the formation ERα and ERβ homodimers 
and for contact with the ligand.  This provides a link between ligand binding and 
dimerization.  The binding of an agonist to ER induces a conformational change 
in the dimer that is different from the antagonistic-bound ER dimer structure 
(155, 156).  Agonist induced rearrangement of ER results in formation of a 
specific binding site for coactivators at their respective LXXLL motifs that behave 
as hydrophobic docking motifs that bind the LBD.  
ERα and ERβ can also form heterodimers which bind EREs.  The dimeric 
receptor complex binds DNA and recruits other transcription factors with histone 
acetyltransferase (HAT) activity that initiate changes in chromatin by altering the 
nucleosome position and allowing formation of the preinitiation complex (157).  
Nuclear receptors activate their target genes by stabilizing the preinitiation 
complex through direct interaction with components of the preinitiation complex 
including TFIIB, TBP, TFIID, and TFIIF allowing the recruitment of RNAP II to 
the promoter (158). 
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1.5.3 Classical Genomic Activation Through the Estrogen Receptor 
As indicated above steroid hormone receptor dimers bind specific 
hexanucleotide palindromic half sites called response elements that are 
arranged in a particular motif in chromatin and modulate transcription (152, 159). 
The glucocorticord response element (GRE) was the first to be discovered in the 
MMTV promoter (160, 161).  The GRE contains two short inverted repeats 
separated by three nucleotides.   The progesterone, mineralocorticoid, androgen 
and estrogen receptor have similar response elements (Table 2).   
 
 
Table 2.  Hormone response elements. 
NUCLEAR RECEPTOR RESPONSE ELEMENT DNA SEQUENCE 
Glucocorticoid receptor GRE GGTACAnnnTCTTCT 
Progesterone receptor PRE GGTACAnnnTCTTCT 
Androgen receptor ARE GGTACAnnnTCTTCT 
Estrogen receptor ERE GGTCAnnnTGACC 
 
 
When bound to their specific DNA sequences, nuclear receptors serve as 
on-off switches for transcription within the cell nucleus.  These switches control 
various functions including development and differentiation of skin, bone and 
behavioral centers in the brain, as well as the continual regulation of 
reproductive tissue, including the mammary gland and breast tumors.  There are 
three features that characterize a response element: the sequence of the base 
pairs in the half-site, the number of base pairs between the half-sites and the 
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orientation of the two half-sites.  The receptor dimer recognizes the sequence, 
spacing and orientation of the half-sites within their response element in order to 
bind to the DNA.  Upon binding DNA, the ligand-receptor complex alters the 
transcriptional level by either activating or repressing of the expression of the 
associated gene. 
There are five classes of nuclear receptors based on their dimerization 
and DNA binding properties (129).  The first class binds DNA as heterodimers 
with the retinoic acid X receptor (RXR) on directly repeated half sites separated 
by a spacer of 1-5 base pairs (bp).  The second class of receptors binds DNA as 
heterodimers on inverted responsive sites separated by 1 bp.  The third class 
binds the DNA on direct repeats separated by 1 bp as homodimers. The fourth 
class, to which ER belongs, also binds DNA as homodimers on inverted repeats 
separated by 3 bp ( consensus ERE: 5-GGTCAnnnTGACC-3).  The fifth class 
binds DNA as monomers on a single half site often containing a 3bp 5 
extension.  Although a few estrogen target gene promoters contain perfect  
palindromic ERE sites that match the consensus sequence, most of the 
identified elements are imperfect or nonconsensus.  While the ER-binding 
affinity for imperfect EREs is reduced, these sequences are functional in 
mediating transcriptional activation of reporter genes (162, 163).
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Fig. 13.  Molecular mechanisms of ER genomic action. 
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1.5.4 Non-Classical Genomic Activation of the Estrogen Receptor  
1.5.4.1 ERE1/2-Sp1 Interactions 
In addition to the classical ER-ERE interactions, there are other DNA-
binding dependent pathways that are important for regulation of estrogen-
responsive genes.  One of these mechanisms involves the transactivation of 
genes containing an ERE half site associated with GC-rich elements that bind 
the transcription factor Sp1 (Fig. 13). The distance and the orientation of the half 
ERE and Sp1 motifs can be variable, and the sequence of the ERE can be 
imperfect.  For example, an ERE half site and GC-rich element (Sp1(N)23-ERE) 
were shown to be important for the transactivation of the cathepsin D gene 
promoter.  Mutations of the ERE half site or the Sp1 sites rendered the promoter 
no longer inducible by estrogen (164, 165).   
Subsequent studies have revealed that Sp1(N)x ERE motifs are important 
in the transactivation of other gene promoters including the retinoic acid receptor 
(RAR)α-1  and the heat shock protein 27 promoters (166, 167).  Cooperativity 
with Sp1 has also been reported for promoters containing consensus EREs such 
as the vitellogenin A1 and rabbit uteroglobin promoters (168, 169).  Other 
studies have also shown that Sp1(N)xERE motifs may function as response 
elements for other estrogen regulated nuclear receptors including the 
progesterone receptor (PR).  Promoter A of the PR gene contains an ERE half 
site upstream of two adjacent Sp1 sites.  In this case, mutation of the ERE half 
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site increases transcription substantially suggesting that this ERE plays a limiting 
role in transcription (170).  The testes receptor (TR)-4, an orphan receptor, 
activates the luteinizing hormone receptor gene through an ERE half site located 
50 base pairs (bp) upstream of an Sp1 site, whereas other orphan receptors 
EAR2 and EAR2/COUP-TFI repressed expression of the same gene (171).  Sp1 
has also been shown to mediate DNA-binding dependent transactivation with 
other transcription factors (94, 123)  
1.5.4.2 ER/Sp1 Interactions 
 There is also increasing evidence that ER can function cooperatively with 
Sp1 even in the absence of an ERE (Fig. 13).  Porter et.al identified an 
Sp1(N)10ERE1/2 motif that forms a complex with Sp1 and ER proteins in the 5 
promoter region of the heat shock protein 27 (Hsp 27) gene (167).  Further 
analysis of this region revealed that upon mutation of the ERE1/2 site, estrogen 
responsiveness of the Hsp 27 gene was not lost in transient transfection studies.  
Gel shift mobility studies showed that Sp1 protein formed a protein-DNA 
complex with wild type and mutant Sp1(N)10ERE1/2, and consensus Sp1 
oligonucleotides.  It was also shown that incubation of these complexes with wild 
type ER or an ER mutant with a DNA-binding domain deletion enhanced the 
intensity of the protein-DNA retarded band complex in gel shift mobility assays. 
 Immunoprecipitation studies revealed that there were protein-protein 
interactions between ER and Sp1 proteins, and these interactions were 
observed in the presence or absence of E2.  These data indicate that there is 
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functional cooperativity between Sp1 and ER that facilitates transactivation on 
the Hsp 27 promoter.  This interaction occurs through Sp1 binding to the GC-
box, but not through the ERE1/2 site.  These studies identified a new estrogen-
dependent transactivation pathway that did not require ER binding to the DNA, 
but rather Sp1 protein which bound to the GC-box while interacting with ER 
(172).  There are other genes with GC-boxes that can be activated through an 
ERE-binding independent manner.  Some of these include c-fos (173), 
adenosine deaminase (174), bcl-2 (175), thymidylate synthase (176), cyclin D1 
(177), and cad (178). 
 Saville et.al have shown that both ERα and ERβ interact with Sp1 through 
the C-terminal domain of Sp1 (141).  E2 enhanced ERα/Sp1- but not ERβ/Sp1-
dependent transactivation in breast and prostate cancer cell lines.  Exchange of 
the AF domains of ERα and ERβ proteins produced chimeric proteins ERα/β 
and ERβ/α that were able to associate with the Sp1 protein.  Only the ERα/β 
(not ERβ/α) chimera was able to activate transcription of a GC-rich promoter.   
This indicates that the AF-1 domain of ERα is important for transcriptional 
activation at GC-boxes suggesting that coactivators recruited by the AF-1 region 
play an important role in ERα/Sp1- dependent transactivation. 
 Regulation of ER in the absence of DNA-binding is not limited to ER/Sp1 
interactions.  ER/AP-1 interactions are another extensively investigated ERE- 
independent pathway (Fig. 13).  ER-dependent activation of genes with AP-1 
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elements can be observed for the chicken ovalbumin, human IGF-1, or human 
collagenase genes (179).  In most cases, ER activation mediated by AP-1 can 
be observed with ER mutants lacking the DNA-binding domain (180).  Fos and 
jun are components of the AP-1 complex that bind to the AP-1 DNA element.  
Interactions between ER and AP-1 have been shown to be ER activation 
function-dependent  and independent depending on the receptor, ligand, and 
cell type (181).  ERα can also repress transcription in the absence of DNA-
binding and E2-induced transactivation of erythropoiesis is inhibited by ER 
interactions with GATA-1 (182). 
1.5.5 Membrane ER 
1.5.5.1 Identification 
It has been observed that for some responses the effects elicited by steroid 
hormones are too rapid to be mediated by nuclear ERα-dependent 
transactivation.  These observations have prompted the search for alternate 
pathways to the classical and non-classical genomic ER signaling pathways.  In 
1977, Pietras and Szego described the presence of cytoplasmic membrane 
binding sites for estradiol in endometrial cells (183, 184).  They described an E2 
binding protein, presumably ER, in the cell membrane that triggered rapid 
generation of cAMP.  Subsequent work in the 1980s and 1990s demonstrated 
that estrogen could rapidly activate signaling such as calcium flux (185), cAMP 
generation (186), phospholipase C activation (187), and inositol triphosphate 
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generation (188), leading to the activation of protein kinase C (PKC) and protein 
kinase A (PKA) activation (189, 190).  Research on mERs has provided 
evidence that they are involved in alternative  ER signaling pathways (190). 
These pathways have been called non-genomic or extranuclear pathways.  It 
has also been suggested that the term non-transcriptional may be used 
indicating that DNA binding of the receptors is not required. 
To date, the endogenous membrane ER has not been isolated and therefore 
the structure of mER has not been determined.  However, Pappas et al. used a 
variety of antibodies directed against multiple epitopes of ERα and identified an 
endogenous membrane protein in several cell lines (191).  In 1999, Razandi et 
al. addressed this issue by transfecting Chinese hamster ovary cells, which do 
not normally express ER, with the cDNA for ERα and ERβ (192).  Results of this 
study led to the conclusion that membrane ERs (mER) originate from the same 
transcript as nuclear ER (nER) and have near-identical affinities for 17-β-
estradiol.  This was also the first study to identify a membrane ERβ.   
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1.5.5.2 Membrane Localization 
Growth factors receptors, G-protein coupled receptors (GPCR) and non 
growth factor tyrosine kinases are examples of membrane receptor signaling 
molecules.  Signaling through these molecules occurs in part after localization to 
plasma membrane microstructures known as caveolae (193, 194).  Caveolae 
facilitate signal transduction through the localization of signaling molecules 
(195).  Within the caveolae, signaling molecules interact with caveolins, 
members of a structural coat protein family.  Caveolin-1 serves a scaffold protein 
that associates with and activates a variety of signaling proteins in caveolae 
(195).  Recent studies have shown that ER localizes mainly to caveolae and 
non-caveolar fractions of endothelial cells (196, 197) indicating that membrane 
ERs behave in a similar manner to other membrane receptor signaling 
molecules. 
1.5.5.3 Mechanisms of mER Action 
Generally, it is thought that in order for the effects of a hormone to be 
considered to be non-genomic, the actions of the hormone must be too rapid to 
be compatible with the time it would take to induce RNA and protein synthesis. 
The action of the hormone should also be reproducible in the presence of 
inhibitors of RNA and protein synthesis, further indicating that these processes 
are not required for the hormonal effects (198).  This response usually occurs 
within seconds to minutes after exposure to the hormone as opposed to the 
genomic response that occurs within hours after hormone addition.  However, 
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there are intermediate responses that occur several hours after treatment with 
E2, and these responses are not persistent.  In these cases, the recruitment of 
non-genomic pathways regulates longer-term processes including gene 
expression, cell proliferation, protein and DNA synthesis.  This response 
involves crosstalk between genomic and non-genomic responses and is called a 
membrane-initiated response due to the fact that the hormonal response 
involves membrane protein activity associated with surface receptors such G-
protein coupled receptors (GPCR), growth factor receptors, ion channels, or 
membrane associated signaling complexes (199, 200).  
Other hormones besides E2 are also important for breast cancer growth.  
Growth factors bind to their plasma membrane bound growth factor receptors 
and initiate kinase-signaling cascades that are responsible for the sequential 
phosphorylation and activation of a series of intracellular signaling molecules 
(Fig. 14).   There are several important pathways that are activated by growth 
factors including the phosphotidylinositol-3-kinase (PI3-K) and AKT/PKB 
pathway (201, 202) and the mitogen activated protein kinases (MAPK) ERK1 
and ERK2 (203, 204).  These complex pathways have been shown to 
independently modulate ER activity through phosphorylation (205-207).  
The PI3K/AKT pathway is involved in the mediation of cell survival and 
proliferation signals from a variety of growth factors including insulin, the insulin-
like growth factors (IGF), and members of the epidermal growth factor (EGF) 
family (202).  PI3K/AKT modulates ER by phosphorylation of the serine 167 and  
  
62
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 14. Non-genomic ERα-mediated transactivation.  GPCR (G protein 
coupled receptors), GF (growth factor), GFR (growth factor receptor), TF 
(transcription factor), P (phosphorylation). 
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118 residues of ER (151, 208, 209).  Phosphorylation of the serine residues 
activates ER and allows it to be transcriptionally active.   
IGF-1 induces cell proliferation and/or DNA synthesis of ER-positive breast 
cancer cells and these responses have been shown to be inhibited by PI3K 
inhibitors such as wortmanin and LY294002, as well as antiestrogens, 
demonstrating that the mitogenic activity of IGF-1 is linked to regulation of 
estrogen-responsive genes.   Xie et al. showed that IGF-1 induced expression of 
the adenosine deaminase (ADA) gene in MCF-7 cells was mediated through 
activation of ERα/Sp1 (210).  IGF-1 induced both MAPK and PI3K 
phosphorylation cascades. However, only the MAPK inhibitors inhibited 
transactivation of ADA gene promoter constructs by IGF-1, indicating that 
activation of the ADA gene in MCF-7 cells  is dependent on the MAPK signaling 
pathway (210). 
There is also evidence of ER-growth factor receptor crosstalk.  E2 has been 
shown to induce uterine cell proliferation through the actions of EGF (211).  This 
might occur through mER utilization of the EGF receptor as a signal transduction 
scaffold molecule to effect signaling.  E2 also increases expression of several 
growth factors and their receptors to amplify signals generated through these 
pathways (212, 213).  Therefore growth factor activation of ER and E2 activation 
of growth factor receptors act together to allow crosstalk between ER and 
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growth factor receptors to synergistically activate genes in breast cancer cell 
lines.   
G-protein coupled receptors (GPCR) are a large group of molecules located 
in the plasma membrane.  GPCRs have been recognized as mediators of 
multiple extracellular stimuli including those induced by E2.  For example, it has 
been reported that E2 induces ERK phosphorylation through GPR30, a GPCR 
homologue (214).  Studies in this lab have reported that the transcription of c-fos 
is controlled through the serum-response element that binds the serum-
response factor which recruits Elk-1and the serum response factor accessory 
protein 1 and 2 to mediate induction by growth factors and other extracellular 
stimuli leading to activation of MAPK pathways (215).  Duan et al. reported that 
activation of c-fos by E2 involved non-genomic signaling of ERα through the 
MAPK pathway and phosphorylation and binding of Elk-1 to the serum-response 
element in ERα-positive MCF-7 breast cancer cells (215).  A study by Maggiolini 
et al. reported that E2 activation of c-fos through the MAPK pathway in MCF-7 
cells as well as ERα-negative SKBR3 breast cancer cells involved stimulation 
through GPR30 in an ERα-dependent and independent manner (216).   
ER binding is required in most cases where E2 induces a non-genomic 
response.  Studies in CHO cells showed that E2 bound to ERα or ERβ and 
expression of these mER proteins activated Gαq and Gαs proteins (Fig. 14) 
(192).  This study provided that first direct evidence that mERs are linked to G-
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proteins.  Since these non-genomic signaling responses occur through activation 
of G proteins by E2, this qualifies mER as a member of the GPCR family (192).   
 Membrane ER activation of kinase cascades integrates the membrane 
and nuclear actions of estrogen.  E2 treatment has been shown to stimulate a 
variety of kinase cascades in mammary and prostate cancer cells that are 
responsible for phosphorylation and activation of other kinases and nuclear 
transcription factors including the ELK-1 of c-fos gene in breast cancer cells 
(215).  Qin et al. reported that E2 induced p53 gene expression though E2-
dependent phosphorylation of calmodulin-dependent protein kinase IV (CaMKIV)  
(217).  Other studies in this lab have shown that E2 induces the activation of the 
protein kinase A pathway that in turn phosphorylates transcription factors at the 
gene promoter to promote transactivation.  The cyclin D1 and ornithine 
decarboxylase gene promoters are both activated through multiple enhancer 
elements.  The cyclin D1 gene expression is induced by E2 through ERα/Sp1 
genomic activity as well as non-genomic activation involving  phosphorylation 
through the cAMP-response element (CRE) in ZR-75 breast cancer cells (177).  
The orthinine decarboxylase (ODC) gene is also regulated through PKA 
activation by E2 in MCF-7 cells.  PKA activation of the ODC gene occurs 
primarily through the CCAAT sites that bind NFYA and the LSF sites that bind 
LSF (218).  Recently Li et al.  reported that the lactate dehydrogenase A gene 
was regulated by E2 through activation of CRE though protein kinase C (PKC) 
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(219).  These studies have shown that E2 can induce non-genomic responses 
that activate genomic transcription factors in order to mediate transactivation of 
gene promoters in MCF-7 and ZR-75 breast cancer cells. 
1.5.6 Selective Estrogen Receptor Modulators  
Increasing evidence has shown that although estrogens are associated 
with an increased incidence of breast cancer, steroid hormones are essential for 
many tissue-specific homeostatic responses and hormone replacement therapy 
is routinely used for treating postmenopausal problems such as osteoporosis.  
This has led to development of tissue-specific ER agonists/antagonists that have 
been designated as selective estrogen receptor modulators (SERM).   These 
compounds were first generated in the 1950s as fertility agents.  The beneficial 
effects of antiestrogens in breast cancer patients became apparent shortly after 
they were generated.  However many of the compounds which included stilbene 
analogs also induced significant toxicity (220).  The first studies of the effects of 
antiestrogens on breast cancer patients were published in the early 1970s (221, 
222).  This study introduced a new SERM called tamoxifen (ICI 46,474) which 
30 years later has become the primary treatment for early stage breast cancer in 
women and a chemopreventive agent for women at high risk for this disease 
(223-229).   
Antiestrogens are classified into two groups according to their mechanism 
of action.   Type I antiestrogens include compounds that are agonistic as well as 
antagonistic, while the type II group includes pure antiestrogens that are  
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Fig. 15. Selective estrogen receptor modulators (SERMs). 
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primarily ER antagonists.  Type I antiestrogens affect ER function in part by 
affecting AF-1 and DBD through antiestrogen-induced conformational changes 
that are different from those induced by E2 (141, 230-233). These different 
ligand-induced conformations allow the ER to interact with different sets of 
cofactors that determine whether the effects will be agonistic or antagonistic 
(234). Type II antiestrogens may affect ER function by blocking dimerization 
(235, 236), disrupting nuclear localization of ER (237), and inducing rapid 
degradation of ER in cultured cells or in vivo (238, 239). 
Tamoxifen (Fig. 15) is an example of a type I antiestrogen.  Tamoxifen 
has been proven to be effective for prevention and treatment for breast cancer 
resulting in a 50 % decrease in the incidence of new breast cancer for up to five 
years (240-242). Unfortunately, prolonged treatment with tamoxifen results in 
tamoxifen resistant tumors (243-245).  It has been shown that although 
tamoxifen acts as an antagonist in the breast, it exhibits partial estrogen agonist 
activity in the rodent uterus (246).  Several  studies have shown that tamoxifen 
causes a low but significant increase in the incidence of endometrial cancer in 
women undergoing tamoxifen treatment for over five years and similar results 
have been reproduced in in vitro and in vivo (247-249).  In contrast tamoxifen 
exhibits estrogenic activity in the bone and decreases osteoporatic fractures by 
maintaining bone density in postmenopausal patients (250).  
Ongoing studies have been focused on developing SERMs that will 
maintain bone density while preventing and inhibiting breast cancer 
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development without causing endometrial cancer.  Results of these studies have 
identified raloxifene (Fig. 15), a SERM that was originally discarded as a breast 
cancer drug.  Raloxifene was shown to maintain bone density in ovariectomized 
rodents as well as decrease the incidence of mammary tumors (251, 252).  
These results have also been observed in clinical studies where osteoporatic 
fractures and mammary tumors were decreased by raloxifene in women at risk 
(253).  Currently, raloxifene is available as a preventive treatment for 
osteoporosis and applications of this drug for treatment of breast cancer will be 
forthcoming. 
 Type II antiestrogens have been termed pure antiestrogens because 
they do not possess partial agonist activity for ER.    ICI 164,384 (Fig. 15) was 
the first antiestrogen to be characterized as an ER antagonist with no discernible 
agonistic effects (254).  ICI 182,780 (Fig.15) was found to be the most potent 
and among the more promising new antiestrogens for the treatment of breast 
cancer (232). Unlike tamoxifen, these pure antiestrogens exhibit antagonistic 
effects on mammary tumors and are devoid of uterotropic effects; however, they 
lack the beneficial agonistic effects in the bone. Treatment with either ICI 
164,384 or ICI 182,780 resulted in the inhibition of estrogen responsive genes in 
the breast and uterine tissue (164, 255-261).  However, in some cases the pure 
antiestrogens behaved as ER agonists rather than that ER antagonists  and 
there are some genes that are inducible by ICI 182,780 and estrogens (262). 
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1.6 Aryl Hydrocarbon Receptor 
 
1.6.1 AhR-Mediated Carcinogenesis or Anti-carcinogenesis 
The aryl hydrocarbon receptor (AhR) is a ligand-inducible transcription 
factor that was first identified by Poland et al. in 1976 in the hepatic cytosol of 
mice using [3H]-2,3,7,8-tetrachlorodibenzo-ρ-dioxin (TCDD) (Fig. 16) as a 
radioligand (263).  The AhR plays a role in the response to certain foreign  
chemicals including polychlorinated biphenyls (PCBs) and polycyclic aromatic 
hydrocarbons (PAHs).  TCDD is the most toxic member of the polychlorinated   
dibenzo-ρ-dioxins (PCDD) and dibenzofuran (PCDF) family of chemicals that are 
formed as by-products of industrial processes and during combustion (264). 
TCDD has been used as a prototype to study the mechanism of action of this 
group of compounds.  PCDDs and PCDFs are also byproducts in some 
herbicides and pesticides, and due to their widespread use and environmental 
persistence, these compounds are routinely detected as contaminants in fish, 
wildlife, human adipose tissue, serum and milk (265).   
Individuals most highly exposed to PCDDs/PCDFs include industrial 
workers involved in the manufacture of products that contain these compounds 
as contaminants, herbicide sprayers, and several groups that were accidentally 
exposed to these compounds.  The most famous exposure to PCDDs/PCDFs  
was associated with their presence in Agent Orange, a herbicide used in 
Vietnam to kill the thick vegetation so that the U.S armed forces could better 
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detect their enemies.  This massive exposure resulted in unwanted side effects 
in members of the U.S armed forces as well as the Vietnamese population that 
included  immunosuppressive effects, hepatotoxicity and porphyria, tumor 
promotion, hyperplastic effects, reproductive and developmental effects, 
neurotoxicity, chloracne and other dermal effects (266).  
Although in recent years there has been much debate about the toxicity of 
TCDD, in 1997 the International Agency for Research on Cancer (IARC) 
concluded that TCDD was a human carcinogen (264).  This was determined 
from animal studies and the increased cancer mortality rates in industrial 
workers who were exposed to dioxins.  Several studies showed that TCDD is not 
genotoxic and is more likely a tumor promoter.  Kociba et al. reported that TCDD 
induced liver tumors in female Sprague-Dawley rats but not in male rats (267).  
In contrast, dietary exposure to TCDD decreased the rates of spontaneous 
mammary and uterine tumors in female Spague-Dawley rats suggesting that 
TCDD may be antiestrogenic in these two E2-responsive tissues (268-271). 
 TCDD and other AhR ligands including 6-methyl-1,3,8-trichlorodibenzofuran 
(MCDF, Fig. 14) and diindolymethane (DIM, Fig. 14) inhibit 7,12-
dimethylbenzanthracene (DMBA)-induced growth.  DMBA is a chemical used to 
induce mammary tumors in female Sprague-Dawley rats (269, 271, 272).  A 
study conducted by Holcomb et al. indicated that in rats treated with a 
carcinogenic dose of DMBA  in order to stimulate mammary tumors, TCDD 
decreased  tumor volumes and in some cases small tumors disappeared after 3 
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weeks of TCDD treatment compared to the control group treated with the corn 
oil vehicle (271).  6-MCDF is a non toxic analog of TCDD that has been 
developed for potential use as treatment for breast cancer and has been found 
to significantly inhibit tumor growth in the DMBA-mammary tumor model (272, 
273). Other TCDD analogs are derivatives of indole-3-carbinol (I3C) (Fig. 16), a 
component of brassica vegetables.  I3C itself weakly binds AhR.  However in the 
acidic environment of the intestinal gut, I3C metabolites, including DIMs, exhibit 
higher binding affinity for AhR (264).  Several studies have indicated that I3C 
and its metabolites can inhibit mammary tumor formation and growth by 
inhibiting ER activity (269, 274-277).  
 AhR agonists also inhibit E2-induced responses in the rat uterus.  TCDD 
decreased E2-induced nuclear and cytosolic ER levels, peroxidase activity, EGF 
receptor, and c-fos mRNA levels in the rat uterus (278-281).  Treatment with 
TCDD also decreased E2-induced uterine weight changes and uterine ER levels 
in mice (282, 283). 
1.6.2 Inhibitory AhR/ER Crosstalk 
TCDD and related compounds have been used to study AhR-mediated 
responses in ER-positive and ER-negative human breast cancer cell lines.  
Gene expression studies indicate that treatment with AhR agonists increased 
the expression of CYP1A1 mRNA and protein in ER-positive and some ER-
negative breast cancer cell lines (284).  The ER-positive MCF-7 and T47D 
breast cancer cell lines express functional AhR and treatment of these cells with 
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TCDD induced CYP1A1 gene expression (285-287).  Moreover, in cells 
cotreated with E2 plus TCDD there was significant inhibition of  E2-induced cell 
proliferation (287-290), secretion of tissue plasminogen activator (288), 
cathepsin D secretion and mRNA (291), progesterone receptor (PR) mRNA and 
protein levels (292) and downregulation of ER protein (290, 293-295). TCDD 
was also found to inhibit E2-induced cell cycle responses, enzymes and also 
blocked hormone-induced G1 to S progression in breast cancer cells (296).  
1.6.3 AhR and Arnt Structure 
The AhR and AhR nuclear translocator (Arnt) proteins are members of the 
basic helix-loop-helix (bHLH) family of transcription factors that contain several 
domains which are responsible for DNA binding, ligand binding, and interaction 
with other proteins that are required for ligand-induced transactivation (Fig. 17).  
The bHLH region is found in the N-terminal region of the AhR protein and is 
responsible for dimerization with the Arnt and DNA binding.  The HLH region is 
mainly responsible for interactions with Arnt, while the basic region is required 
for interaction with DNA. Deletion analysis revealed that both the α-helices in the 
bHLH region are required for dimerization with Arnt and DNA binding (297).  
 Arnt was first identified as the non-ligand binding component of the 
transformed AhR DNA binding complex (298-300).  In 1991, Arnt was cloned 
and sequenced and was found to be structurally similar to AhR (Fig. 17).  Arnt 
also possesses a bHLH domain in the N-terminal region, a PAS domain, and a 
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transactivational domain in the C-terminal region of the protein (301-303) .  Like 
the AhR protein, both α-helices in the bHLH region of Arnt are required for 
dimerization with AhR and the basic region is required for DNA binding (304).  
Subsequent studies have shown that Arnt (also known as hypoxia inducible 
factor-1B (HIF-1β)) forms a heterodimer with HIF-1α to mediate hypoxia-
inducible gene expression.  Arnt is also a heterodimeric partner for many other 
bHLH genes (305, 306). 
 
 
 
 
 
 
 
 
Fig. 17.  Structural and functional domains of AhR and Arnt (237). 
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309). The PAS domain contains two imperfect 51 amino acid repeats that are 
referred to as PAS A and PAS B.  While the rest of the protein structures 
between AhR and Arnt are similar, their PAS domains are functionally different.  
In the inactive form, the AhR interacts with two heat shock proteins 90 (Hsp90) 
in the cytosol. One of the Hsp90 proteins interacts with the PAS B domain while 
the other Hsp90 protein interacts with the bHLH region (297, 301, 310, 311).  
The PAS B domain is also required for ligand binding and DNA binding activities 
of the AhR.  In contrast, the PAS B domain of Arnt does not bind ligand or 
Hsp90 (297, 312-317).   
In most species, the N-terminal region of the AhR is highly homologous.  
Most of the differences occur in the C-terminal region that contains multiple 
transcriptional activation domains, including the glutamine (Q) rich domain and a 
reversible domain that specifically represses transactivation by AhR and Arnt in 
the absence of ligand (301, 303, 318, 319).  The transactivation domains of AhR 
and Arnt are also functionally different.  Transactivation by Arnt requires the 
intact protein while the C-terminal region of AhR is sufficient for transactivation in 
the presence ligand and Arnt. 
1.6.4 The Role of AhR and Arnt in Mammalian Development 
AhR null mice have been generated independently by several groups in 
order to provide information on the role of the AhR in mammalian development.  
Fernandez-Salguero et al. observed 40-50% mortality of AhR knockout pups in 
the first two weeks (320).  These studies indicated that in animals that do not 
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express the AhR there is reduced liver size, decreased growth rate over the first 
four weeks, and resistance to induction of CYP1A1 and CYP1A2 gene 
expression by TCDD and TCDD-induced toxicities (320-322).  Overall, the AhR 
knockout mice were viable suggesting that the AhR either serves a redundant 
function or is not essential to life (320, 323).  In contrast, the generation of Arnt 
deficient mice resulted in the death of mice in utero prior to day 10.5 of gestation 
and this may be related to the critical role of Arnt in regulating expression of 
genes during hypoxia (324, 325).   
1.6.5 Mechanism of AhR Mediated Transactivation 
The unliganded Ah receptor is generally found in the cytosol in a 290- to 
300-kDa complex that has low DNA binding affinity and contains the heat shock 
90 protein and a novel protein known as AIP (AhR-interacting protein) at low 
temperature.  The Hsp90 proteins serve as chaperones that keep the AhR in the 
cytosol in its inactive form.  Upon increase of temperature or treatment with 
TCDD the AhR is dissociated from the heat shock proteins and is associated 
with the Arnt protein to form a 180- to 200-kDa complex that is then translocated 
into the nucleus.  This AhR/Arnt complex exhibits a higher affinity for DNA 
binding than the AhR/Hsp90 complex.   
Most initial studies on the molecular biology of AhR action were determined 
by analysis of the 5-flanking region of the CYP1A1 gene.  The result of these 
studies identified cis-acting genomic dioxin or xenobiotic responsive elements 
(DRE/XRE) that interacted with the AhR/Arnt complex resulting in transcriptional  
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Fig. 18.  Mechanisms of AhR transactivation and inhibition of ERα-mediated 
responses. 
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activation of the CYP1A1 gene.  Although the AhR is not a member of the 
steroid hormone nuclear receptor family, its transactivation is similar to that of 
steroid receptors in that a heterodimer must be formed in order to bind to the 
responsive element in the nucleus (Fig. 18).  Promoter regions of many genes 
contain functional DRE/XREs (consensus sequence TNGCGTG) that bind the 
ligand-activated AhR complex and some of these Ah-responsive genes include 
CYP1A2, CYP1B1, glutathione S-transferase, and aldehyde-3-dehydrogenase 
(270, 326, 327).   
1.6.6 Mechanisms of Inhibitory AhR-ERα Crosstalk 
In most cases where genes such as CYP1A1 are activated by the Ah 
receptor, the AhR/Arnt complex interacts with a dioxin response element located 
in the gene promoter.  Binding of the AhR/Arnt heterodimer to the DRE/XRE 
remodels the chromatin structure and facilitates the association of other 
transcription factors in the promoter region in order to activate transcription 
(328).  However there are instances where AhR/Arnt agonists act as inhibitors 
rather than activators of ERα-mediated gene expression (262, 268, 329-334).   
Studies in this laboratory have identified inhibitory dioxin responsive elements 
(iDRE) that would account for the inhibitory mechanism of AhR-ERα crosstalk 
(Fig. 18).  TCDD inhibited E2-induced secretion and transcription of the 
cathepsin D gene in MCF-7 cells (165, 289, 335). The cathepsin D promoter 
contains an estrogen-responsive ERE1/2(N23)Sp1 motif that is inhibited by 
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cotreatment with TCDD.  Examination of the sequence between the ERE half-
site and the GC-rich Sp1 binding sites revealed the presence of an overlapping 
core inhibitory DRE motif (iDRE).  Mutation of the DRE motif had no effect on 
reporter gene activity induced by E2 or DNA binding in gel shift mobility assays.  
However, TCDD was no longer able to disrupt E2-induced responses (165). The 
AhR/Arnt complex interacts with the iDRE on the 5-flanking region of many  
other genes including, c-fos, pS2, and Hsp 27 genes in order to inhibit ER-
mediated transactivation of these genes (262, 291, 331).  
There are several E2-induced genes that do not contain iDREs but are still 
inhibited by AhR agonists, and inhibitory AhR-ERα crosstalk may involve the 
proteasome-dependent degradation of ERα induced by both AhR and ERα 
agonists (Fig. 18) (264, 336).  Wormke et al. showed that both E2 and TCDD 
activated proteasome-dependent degradation of ERα and AhR proteins 
respectively in MCF-7 and T47D cells (135).  This study indicated that although 
TCDD was involved in the degradation of both ERα and AhR proteins, E2 was 
only involved in the proteasome degradation of ERα protein.  These results 
indicated that proteasome degradation of ERα by TCDD may be a limiting factor 
that significantly contributes to AhR-mediated inhibition of E2 responses. 
It has also been hypothesized that ligand bound AhR may compete with ER 
for coactivators leading to decreased E2-induced transactivation. Studies in this 
lab and others have revealed that AhR interacts with ERα coactivators such as 
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SRC-1 and ERAP140 (312, 337, 338)  and the corepressor SMRT (312).  These 
interactions may also contribute to inhibition of ER-mediated responses by AhR 
agonist.   
Coimmunoprecipitation and GST-pulldown studies revealed that the  
AhR/Arnt complex  interacted with ER and this interaction may contribute to 
AhR/ER crosstalk (339). Klinge et al. reported that the AhR interacted directly 
with ERα and inhibited E2-induced transactivation of genes with EREs such as 
pS2 and c-fos.  However, Arnt did not interact with ER.  Inhibition of gene 
expression may be caused by AhR sequestration of ERα and thereby inhibiting 
ER binding to DNA or interactions with other transcription factors including the 
basal transcription machinery.  In contrast, studies by Ohtake et al. indicate that 
AhR/ERα interactions may not be inhibitory but estrogenic (340).  This study 
reported that AhR/Arnt directly associated with ERα and ERβ in MCF-7 cells 
treated with the AhR agonist 3-methylcholanthrene and that this complex was 
able to bind estrogen responsive gene promoters and recruit coactivators.  This 
result was in agreement with other studies indicating that AhR agonists promote 
AhR/ER interactions (339).  However, their observations that AhR agonists 
mediate estrogen-like responses have not been observed in research in this 
laboratory or by other investigators, and this is currently being reexamined in this 
laboratory (262, 268, 329-334).  
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AhR and Arnt have been shown to interact with the zinc finger domain of 
Sp1 through their basic HLH/PAS domains (341).  These interactions may inhibit 
ER-mediated gene transactivation through competition with ER for Sp1.  In 
genes where transactivation occurs through ERα/Sp1 interactions, the presence 
of the AhR and its interactions with Sp1 may not allow formation of the 
transcriptionally active ERα/Sp1 complex but a repressive AhR/Sp1 complex.  
Studies in this research project are focused on the cell context-dependent 
mechanisms of hormone-induced expression of E2F-1 and inhibition of this 
response by AhR agonists.  The mechanisms of inhibitory AhR-ERα crosstalk 
will also be investigated and this will include studies on ERα/Sp1- AhR/Sp1 
complex formation since hormone activation of E2F-1 is, in part, dependent on 
ERα/Sp1 (342, 343). 
1.7 Research Objectives 
Cell cycle progression and proliferation of tumors and normal tissues/cells 
are controlled by a constellation of factors that coordinately regulate one or more 
growth-dependent pathways (344-348).   Many of the critical genes required for 
cell proliferation modulate progression through different phases of the cell cycle, 
and E2F family members play a critical role in G1→S phase progression (349-
352).  Interactions of retinoblastoma (Rb) proteins with E2F suppresses 
transcription of genes which contain critical E2F binding sites; however, 
phosphorylation of Rb results in dissociation of the Rb-E2F complex and 
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subsequent upregulation of E2F-dependent genes (352-354).  E2F-1 was the 
first E2F family member identified (355-357), and several studies have 
characterized E2F-1-dependent expression of genes required for cell 
proliferation, and this is related to the oncogenic activity of this transcription 
factor (349-352). 
 Although regulation of E2F-1-dependent transactivation is closely linked 
to Rb phosphorylation, E2F-1 expression is also modulated by many other 
nuclear transcription factors and coregulatory proteins (358-362).  For example, 
p300/CBP-associated factor (P/CAF) acetylates E2F-1 and this enhances the 
transcriptional activity of E2F-1 in U20S cells (361). 
 Johnson and coworkers (358, 359) investigated cell cycle-dependent 
activity of constructs containing E2F-1 gene promoter fragments in REF-52 cells 
treated with serum and based on 5'-deletion analysis, the -204 to -122 region of 
the promoter was required for maximal responses.  The E2F-1 binding sites in 
the proximal region of the promoter were primarily required for negative control 
of the E2F-1 promoter in G0 and early G1.   
1.7.1 Objective 1 
Research in this laboratory showed that 17β-estradiol (E2) induced E2F-1 
mRNA and protein levels in estrogen receptor (ER)-positive MCF-7 breast 
cancer cells, and the induction response was linked to cooperative 
ERα/Sp1/NFY interactions which involved three GC-rich (-169 to -111) and two 
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CCAAT (-122 to -54) binding sites (342).  The downstream CCAAT sites bound 
NFYA and were required not only for hormone-dependent activation of E2F-1 
but also for basal activity of the E2F-1 promoter.   Studies in this laboratory have 
also used ER-positive ZR-75 breast cancer cells for investigating molecular 
mechanisms of hormone-induced transactivation of E2-responsive genes.  MCF-
7 and ZR-75 cells are both luminal epithelium cell lines that have been derived 
from human mammary tumors.  Clinical studies have shown that women who 
have been diagnosed with ERα-postive breast cancer sometimes respond 
differently to chemotherapeutics due to the induction of different signaling 
pathways by growth regulators that lead to tumor formation (363).  Other studies 
have also indicated that differences in protein expression in ERα-positve breast 
cancer cells lines can also determine the cells response to homornal treatment  
For example, de Cremoux et al. used two MCF-7 cell subtypes, the parental 
MCF-7 and a mutant MCF-7 cell lines, which had similar expression levels of 
ERα but different responses to hormonal therapy (364).  There were differences 
in the expression of several genes including increased expression of multidrug 
resistance gene 1 and breast cancer antiestrogen resistance gene 1in the 
mutant MCF-7 cell line, indicating that the hormonal regulation and responses to 
antiestrogens of some ERα-positive breast cancer cell lines may depend on the 
cell context.  The first objective of this study is to compare hormonal activation of 
constructs containing the GC-rich and CCAAT motifs in the -173 to -54 region of 
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the E2F-1 gene promoter in ERα positive MCF-7 and ZR-75 cells.  We 
hypothesized that although both cell lines share similar expression patterns of 
proteins such as ERα, AhR, and Arnt, some of the differences such as 
increased Sp1 protein expression in ZR-75 cells may lead to cell context-
dependent differences in hormonal activation of E2F-1.  
1.7.2 Objective 2 
Studies in this laboratory have investigated an indirect inhibitory 
mechanism that involves the ligand-activated aryl hydrocarbon receptor (AhR) 
(334).  The AhR agonist 2,3,7,8-tetrachlorodibenzo-ρ-dioxin (TCDD) inhibits E2-
induced expression of multiple genes/proteins including progesterone receptor, 
prolactin receptor, cell cycle proteins, cathepsin D, c-fos, pS2, and heat shock 
protein 27 in breast cancer cells (262, 291, 292, 296, 331, 332, 365, 366).  The 
mechanisms of AhR-ERα crosstalk for some genes involve direct interaction of 
the AhR complex with inhibitory dioxin response elements (iDREs) in target 
gene promoters (165, 262, 291, 331, 332, 367) and also induction of 
proteasome-dependent degradation of ERα which becomes limiting in breast 
cancer cells (135, 368).   
Troester et al. reported that MCF-7 and ZR-75 cell lines responded to 
chemotherapeutics better than basal epithelium cell lines that did not express 
ERα (369).  This data is consistant other studies indicated that ERα-positive cell 
lines respond to chemotherapeutics whereas ERα-negative cells do not respond 
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well.  This study investigates the antiestrogenic effects of TCDD on E2-induced 
expression of E2F-1 in MCF-7, ZR-75 and Schneider SL-2 cells.  We 
hypothesized that since E2-induced E2F-1 gene expression in a genomic and 
non-genomic manner, TCDD would inhibit E2-induced genomic and non-
genomic mechanisms of E2F-1 gene expression. 
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CHAPTER II 
 
METHODS AND MATERIALS 
 
2.1 Chemicals and Cells   
MCF-7, ZR-75, and Schneider SL-2 cells were obtained from the American 
Type Culture Collection (ATCC, Manassas, VA).  MCF-7 cells were maintained 
in DME/F12 medium with phenol red and supplemented with 2.2 g/l sodium 
bicarbonate, 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic 
solution (Sigma Chemical Co., St. Louis, MO) in an air:carbon dioxide (95:5) 
atmosphere at 37°C.  ZR-75 cells were maintained in RPMI medium 
supplemented with 10% FBS, 2.2 g/l sodium bicarbonate, 4.5 g/l glucose, 0.11 
g/l pyruvic acid, 2.38 g/l HEPES, and 10 ml/l antibiotic-antimycotic solution in an 
air:carbon dioxide atmosphere at 37°C.  For transient transfection studies, MCF-
7 and ZR-75 cells were grown for 1 day in DME/F12 medium without phenol red 
and 2.5% FBS treated with dextran-coated charcoal, and for Western and 
Northern blot analysis, the same media without phenol red and FBS-free media 
was used for at least 48 h prior to treatment with E2 and other chemicals.  SL-2 
cells were cultured at room temperature in Schneiders Drosophila medium 
(InVitrogen, Carlsbad, CA) supplemented with 10% heat-inactivated FBS and 10 
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ml/l antibiotic-antimycotic. E2 was purchased from Sigma Chemical Co and 
TCDD was prepared in this lab and was >98% pure as determined by high-
pressure liquid and gas chromatography.  Dimethyl sulfoxide (DMSO) was used 
as a solvent for E2, SQ22536, 8-bromo-cAMP and MG132.  SQ22536, 8-bromo-
cAMP and MG132 were purchased from Calbiochem (La Jolla, CA).    ERα, 
AhR, Sp1, Sp3, and NF-1 antibodies were obtained from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA).  The NFYA antibody was purchased form 
Rockland, Inc. (Gilbertsville, PA).  The PKA and phospho-PKA antibodies were 
purchased from Calbiochem.  Luciferase and β-galactosidase enzyme assay 
systems are purchased from Promega Corp. (Madison, WI) and the cAMP 
enzyme immunoassay (EIA) system was purchased from Amersham 
Biosciences (Piscataway, NJ). 
2.2 Cloning and Plasmids   
 The wild-type ER (hER) expression plasmid was provided by Ming-Jer 
Tsai (Baylor College of Medicine, Houston, TX).  Recombinant ER was obtained 
from Pan Vera Corp. (Madison, WI).  The ER deletion mutants HE11, HE15, and 
HE19 were provided by Pierre Chambon (Institut de Genitique et de Biologie 
Moleculaire et Cellulaire, Illkirch, France).  The constructs pE2F-1a, pE2F-1b, 
and pE2F-1d were kindly provided by Dr. J.R. Nevins (Duke University, Durham, 
NC).  The pE2F-1c construct were made by RT-PCR starting with the E2F-1 
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cDNA (forward primer:  5-CCGCCATTGGCCGTACCGCCCC-3; reverse 
primer:  5-
GATCTTCCCGGCCACTTTTACGCGCCAAA-3) and inserted into pGL2 basic 
vector (Promega Corp.) at Sac1 and BglII cloning sites.  The remaining E2F-1 
promoter constructs (pE2F-1e, pE2F-1f, pE2F-1g, pE2F-1h, pE2F-1hm1, pE2F-
1hm2, pE2F-1hm3, pE2F-1hm4, pE2F-1hm5, pE2F-1i, pE2F-1j, pE2F-1jm1, pE2F-
1jm2, pE2F-1k, pE2F-1l) were made by inserting synthetic oligonucleotides into 
the pGL2 basic vector digested with SacI and BglII enzymes at the cloning sites 
(Table 3).  Oligonucleotides were synthesized by Integrated DNA Technologies, 
Inc. (Coralville, IA).  Resulting plasmids were sequenced at the Gene 
Technology Laboratory (Texas A&M University, College Station, TX) to confirm 
appropriate insertion of the oligonucleotide inserts.  The sequences of Sp1 
(CCGCCCC) and CCAAT protein-binding sites in the E2F-1 promoter have been 
mutated into CCtttCC and atgcT, respectively, in all constructs containing 
mutations in these sites.  The PKA expression plasmid was provided by Dr. R. 
Maurer (Oregon Health Sciences University, Portland, OR).  The expression 
plasmids of wild type NFYA, NF-YB and mutant NFYA (∆4YA13m29) and control 
plasmid (∆4YA13) were kindly provided by Dr. Roberto Mantovani (Universita di 
Milano, Milan, Italy).  Gal4-luc was provided by Dr. M. Mayo (University of North 
Carolina, Chapel Hill, N.C).  The pM-NFYA expression plasmid was made by 
PCR using primers (forward primer:  5-GGA ATT CAT GGA GCA GTA TAC 
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GAC A-3; reverse primer:  5-GCT CTA GAT TAG GAA ACT CGG ATG A-3) to 
amplify full length NFYA using the NFYA expression plasmid as a template.  The 
amplified products were cloned into the pM vector (Clontech, Palo Alto, CA) 
between EcoRI and XbaI cloning sites. The pPAC and pPAC/Sp1 expression 
vectors were provided by Dr. Robert Tjian (University of California-Berkeley, 
Berkeley, CA) and the pPAC/hERα expression plasmid was made in this 
laboratory by releasing the hERα coding sequence from the hERα expression  
plasmid and cloning it into the XhoI site of pPAC. 
 
Table 3.  Wild type E2F-1 and deletion and mutation constructsa. 
Construct Oligonucleotide Sequence 
pE2F-1b 
-242/+77 
cgggctgggggcggggagtcagaccgcgcctggtaccatccggacaaagcctgcgcgcgccccgccc
cgccattggccgtaccgccccgcgccgccgccccatctcgcccctcgccgccgggtccggcgcgttaaa
gccaataggaaccgccgccgttgttcccgtcacggccggggcagccaattgtggcggcgctcggcggct
cgtggctctttcgcggcaaaaaggatttggcgcgtaaaagtggccgggactttgcaggcagcggcggcc
gggggcggagcgggatcgagccctcgccgaggcctgccgccatgg 
 
pE2F-1c 
-177/+10 
 
cccgccattggccgtaccgccccgcgccgccgccccatctcgcccctcgccgccgggtccggcgcgtta
aagccaataggaaccgccgccgttgttcccgtcacggccggggcagccaattgtggcggcgctcggcg
gctcgtggctctttcgcggcaaaaaggatttggcgcgtaaaagtggccgg 
 
pE2F-1d 
-122/+77 
 
gtccggcgcgttaaagccaataggaaccgccgccgttgttcccgtcacggccggggcagccaattgtgg
cggcgctcggcggctcgtggctctttcgcggcaaaaaggatttggcgcgtaaaagtggccgggactttgc
aggcagcggcggccgggggcggagcgggatcgagccctcgccgaggcctgccgccatgg 
 
pE2F-1e 
-242/-122 
cgggctgggggcggggagtcagaccgcgcctggtaccatccggacaaagcctgcgcgcgccccgccc
cgccattggccgtaccgccccgcgccgccgccccatctcgcccctcgccgccg 
 
pE2F-1f 
-242/-122 
-20/0 
cgggctgggggcggggagtcagaccgcgcctggtaccatccggacaaagcctgcgcgcgccccgccc
cgccattggccgtaccgccccgcgccgccgccccatctcgcccctcgccgccgaaaaaggatttggcgc
gtaa 
 
pE2F-1g 
-173/-54 
ccattggccgtaccgccccgcgccgccgccccatctcgcccctcgccgccgggtccggcgcgttaaagc
caataggaaccgccgccgttgttcccgtcacggccggggcagccaattgtg 
 
pE2F-1h 
-169/-54 
tggccgtaccgccccgcgccgccgccccatctcgcccctcgccgccgggtccggcgcgttaaagccaat
aggaaccgccgccgttgttcccgtcacggccggggcagccaattgtg 
 
pE2F-1 
hm1 
-169/-54 
 
tggccgtacctttccgcgccgccgccccatctcgcccctcgccgccgggtccggcgcgttaaagccaata
ggaaccgccgccgttgttcccgtcacggccggggcagccaattgtg 
 
 . 
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Table 3. Continued. 
Construct Oligonucleotide Sequence 
pE2F-1 
hm2 
-169/-54 
 
tggccgtaccgccccgcgccgcctttccatctcgcccctcgccgccgggtccggcgcgttaaagccaata
ggaaccgccgccgttgttcccgtcacggccggggcagccaattgtg 
 
pE2F-1 
hm4 
-169/-54 
 
Tggccgtaccgccccgcgccgccgccccatctcgcccctcgccgccgggtccggcgcgttaaagatgct
aggaaccgccgccgttgttcccgtcacggccggggcagccaattgtg 
pE2F-1 
hm5 
-169/-54 
 
tggccgtaccgccccgcgccgccgccccatctcgcccctcgccgccgggtccggcgcgttaaagccaat
aggaaccgccgccgttgttcccgtcacggccggggcagatgcttgtg 
 
pE2F-1i 
-173/-91 
ccattggccgtaccgccccgcgccgccgccccatctcgcccctcgccgccgggtccggcgcgttaaagc
caataggaaccgcc 
 
pE2F-1j 
-146/-54 
gccccatctcgcccctcgccgccgggtccggcgcgttaaagccaataggaaccgccgccgttgttcccgt
cacggccggggcagccaattgtg 
 
pE2F-1 
jm1 
-122/-54 
 
ggtccggcgcgttaaagccaataggaaccgccgccgttgttcccgtcacggccggggcagccaattgtg 
 
pE2F-1 
jm2 
-146/-54 
 
gccccatctcgcccctcgccgccgggtccggcgcgttaaagatgctaggaaccgccgccgttgttcccgtc
acggccggggcagatgcttgtg 
 
pE2F-1k 
-169/-111 
tggccgtaccgccccgcgccgccgccccatctcgcccctcgccgccgggtccggcgcgt 
 
pE2F-1l 
-173/-111 
ccattggccgtaccgccccgcgccgccgccccatctcgcccctcgccgccgggtccggcgcgt 
 
aGC-rich, CCAAT, and HES-1 promoter elements are underlined.2.3  
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2.3  Transient Transfection and Luciferase Assays  
MCF-7 and ZR-75 cells were seeded in 12 well Falcon plates in DME/F12 
medium supplemented with 2.5% dextran-coated charcoal FBS and grown until 
they were 70% confluent.  Plasmids (500 ng) were transiently cotransfected with 
the ER expression plasmid (500 ng) using the calcium phosphate method.  Cells 
were incubated for 4 to 6 h and then shocked with 25% glycerol in phosphate-
buffered saline (PBS) and treated with DMSO, 10 nM E2, 10 nM TCDD, and 
TCDD plus E2 and kinase inhibitors and activators or their combinations in 
DMSO for 44 to 48 h.  SL-2 cells were transfected with the E2F-1 promoter 
construct (500 ng), and cotransfected with pPAC plasmids using the calcium 
phosphate method. The SL-2 cells were incubated for 16 h and treated with 
DMSO, 10 nM E2, 10 nM TCDD, and TCDD plus E2 for 44 to 48 h.  The cells 
were harvested in cell lysis buffer (Promega Corp.)  Cell lysates were prepared 
by freeze-thawing followed by centrifugation at 14,000 X g for 1 min.  Luciferase 
activity was then determined in a luminometer (Packard Instruments Co.  
Meriden, CT) with a luciferase assay kit (Promega Corp.) and normalized to β-
galactosidase enzyme activity obtained after transfection with a β-galactosidase-
lacZ plasmid (500 ng).  The pcDNA3.1/His/LacZ control vector containing the 
gene for b-galactosidase and a CMV promoter  was from Invitrogen (Carlsbad, 
CA).  The experiments for each treatment group were carried out at least in 
triplicate. 
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2.4 Northern Blot Analysis 
MCF-7 and ZR-75 cells were seeded and grown as described above and 
treated with DMSO, 10 nM E2, 10 nM TCDD, and TCDD plus E2.  RNA was 
extracted using an RNA extraction kit from Tel-Test (Friendswood, TX).  Total 
RNA (25 µg) was separated on a 1.2% agarose/1 M formaldehyde gel and 
transferred onto nylon membrane.  The membrane was then exposed to UV light 
for 5 min to crosslink RNA to the membrane and then baked at 80°C for 2 h.  
The membrane was prehybridized in a solution containing 0.1% BSA, 0.1% 
Ficoll, 0.1% polyvinyl pyrollidone, 10% dextran sulfate, 1% SDS, and 5x SSPE 
(0.75 M sodium chloride, 50 mM NaH2PO4, 5 mM EDTA) for 18 to 24 h at 60°C 
and hybridized in the same buffer for 24 h with the [32P]-labeled DNA probe (106 
cpm/ml).  The E2F-1 cDNA probes (21) was labeled with [γ-32P]dCTP using the 
random primed DNA labeling kit (Boehringer-Mannheim, Indianapolis, IN).  The 
resulting blots were visualized and quantitated using a Molecular Dynamics, Inc. 
Storm 860 instrument (Molecular Dynamics, Inc., Sunnyvale, CA).  β-Actin 
mRNA was used as an internal control to standardize E2F-1 mRNA levels. 
2.5  Preparation of Nuclear Extracts 
Nuclear extracts were prepared from cells treated with DMSO or E2.  
Harvested cells were washed twice in 30 ml of HEGD buffer (25 nM HEPES, 1.5 
mM EDTA, 1 mM dithiothreitol, and 10% glycerol, pH 7.6).  The pellet was then 
incubated for 10 min in 1 ml of HED buffer (HEGD without the glycerol).  Cells 
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were then transferred to a 2 ml homogenizing tube and homogenized using a 
Teflon/pestle drill apparatus.  The homogenate was transferred to a centrifuge 
tube, centrifuged at 4000 X g for 10 min, washed twice with HEGD, and finally 
resuspended in 2 ml of HEGD containing 0.5 M sodium chloride and allowed to 
incubate at 4°C for 1 h. 
2.6  Gel Mobility Shift Assay with Nuclear Extracts  
Synthetic oligonucleotides were synthesized, purified, annealed and labeled 
at the 5-end using T4-polynucleotide kinase and [γ-32P] ATP.  DNA binding was 
measured using a gel retardation assay.  Nuclear extracts were incubated in 
HEGD with 1 µg poly[d(I-C)] and 1 mM ZnCl for 10 min on ice to bind 
nonspecific DNA-binding proteins.  Then 200-fold excess of unlabeled wild type 
or mutant oligonucleotide competitors for the competition experiments were 
incubated with the nuclear extracts for 5 min on ice.  The mixture was then 
incubated for 15 min at 20°C with 0.1pmol/µl [32P]-labeled DNA probe.  
Antibodies were added for an additional 15 min for the supershift reactions.  The 
reaction mixture was then loaded onto a 5% polyacrylamide gel and 
electrophoresed at 150 V for 2.5 h in 0.9 M tris-borate and 2 mM EDTA, pH 8.0.  
The gel was dried and protein-DNA complexes were visualized using a 
Molecular Dynamics, Inc. Storm 860 instrument (Molecular Dynamics, Inc., 
Sunnyvale, CA) 
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2.7 Western Blots 
MCF-7 and ZR-75 cells were grown and seeded as described above.  Cells 
were synchronized in FBS-free DME-F12 media for 48 h and treated with 
DMSO, 10 nM E2, 10 nM TCDD, and E2 plus TCDD for various time points. For 
experiments where MG132 was used, cells were pretreated with 10 µM MG132 
and DMSO for 30 min and then treated with DMSO, E2, TCDD, and E2 plus 
TCDD for various time points.  The cells were then lysed in ice-cold lysis buffer 
(50 mM HEPES [pH 7.5], 500 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10% (v/v) 
glycerol, and 1% (v/v) Triton X) supplemented with protease inhibitor cocktail 
(Sigma).  Equal amounts  of protein from each treatment group were boiled in 
1X Laemmli Buffer (50 mM Tris-HCL, 2% sodium dodecyl sulfate (SDS), 0.1% 
bromphenol blue, 175 mM β-mercaptoethanol) and separated by SDS-10% 
polyacrylamide gel electrophoresis (SDS-PAGE), and transferred to a 
polyvinylidene difluoride (PVDF) membrane.  Membranes were blocked in Blotto 
(5% milk, Tris-buffered saline [10 mM Tris-HCL, pH 8.0, 150 mM NaCl] and 
0.05% Tween 20) and probed with primary antibodies (ERα, AhR, and Sp1).  
Following incubation with peroxidase-conjugated secondary antibodies, 
immunoglobulins were visualized using the Western Lightning ECL detection 
system (PerkinElmer Life Sciences, Inc., Boston, MA).  Quantitation was 
performed using a Sharp JX-330 scanner (Sharp Electronics, Mahwah, NJ) and 
Zero-D Scanalytics software (Scanalytics Corp. Sunnyvale, CA) 
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2.8  cAMP Enzyme Immunoassay (EIA)   
ZR-75 cells were seeded in 2.5% FBS DME/F12 medium overnight.  The 
cells were then treated with the various compounds for 30, 60, and 120 min.  
The cAMP EIA system (Amersham) was used to determine cAMP level 
according to the suppliers instructions.  The calculations for cAMP levels 
(pmol/mg protein) were based on a standard curve for each experiment. 
2.9  Statistical Analysis   
The statistical difference between different groups was determined by 
ANOVA and Students t test.  The data are expressed as means ± standard 
errors or standard deviations.  At least three determinations were carried out for 
each data point in the transfection and mRNA studies.
 
 *Section 3.1 Modified text and figures are reprinted with permission from Cell 
context-dependent differences in the induction of E2F-1 gene expression by 
17β-estradiol in MCF-7 and ZR-75 cells by Sharon Ngwenya and Steve Safe, 
2003.  Endocrinology, 144, 1675-1685.  Copyright 2003, The Endocrine Society. 
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CHAPTER III 
 
RESULTS* 
 
3.1 Cell Context-dependent Differences in the Induction of E2F-1 Gene 
Expression by 17β-estradiol in MCF-7 and ZR-75 Cells 
3.1.1 Comparative Analysis of the E2F-1 Promoter in MCF-7 and ZR-75 
Cells 
Previous studies show that E2 induces E2F-1 gene expression and 
transactivation in MCF-7 cells.  In order to determine if E2 induced E2F-1 gene 
expression and transactivation, mRNA, protein and transactivation studies were 
conducted in order to compare E2F-1 activation in MCF-7 and ZR-75 cells.  ZR-
75 cells were treated with E2 at different time points and similar results were 
obtained in ZR-75 cells where a > 2.5-fold increase in E2F-1 mRNA levels was 
observed after treatment with 10 nM E2 for 6 h (Fig. 19).  Previous studies 
showed that the -173 to -54 region of the E2F-1 gene promoter exhibited high 
basal activity and, in transient transfection assays in MCF-7 cells, E2 induced 
reporter gene (luciferase) activity (342).  The results in Fig. 20A show that E2F-
1h (containing the -169 to -54 E2F-1 promoter insert) was E2- responsive
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Fig. 19.  Hormone-induced transactivation of E2F-1 mRNA in breast cancer 
cells.  ZR-75 cells were treated with 10 nM E2 for 1, 3, 6 and 24 h, and E2F-1 
and β-tubulin mRNA levels were determined by Northern blot analysis as 
described in the Materials and Methods.  E2F-1 mRNA levels in untreated cells 
(U) are also indicated, and significant (p < 0.05) induction is indicated with an 
asterisk.  Results are expressed as means ± SE for three replicate 
determinations for each treatment group.  The 100% control values were the 
DMSO treatments. 
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Fig. 20.  Deletion and mutation analysis of E2F-1 promoter constructs in MCF-7 
(left) and ZR-75 (right) cells.  Constructs containing wild-type or mutant E2F-1 
gene promoter inserts from the hormone-responsive -169 to -54 region were 
cotransfected with hER and B-galactosidase into MCF-7 or ZR-75 breast cancer 
cells, treated with DMSO (solvent control) or 10 nM E2, and luciferase activity 
was determined as described in the Materials and Methods.  Significant (p < 
0.05) induction by E2 is indicated with an asterisk, and fold induction by E2 is 
also given.  Results are expressed as means ± SE for three replicate 
determinations for each treatment group.  The 100% control values were the 
DMSO treatments for pE2F-1h. 
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in both MCF-7 and ZR-75 cells.  Basal and hormone-induced activity of a series 
of GC- rich and CCAAT mutants (pE2F-1hm1-m5) exhibited both similarities and 
differences in the two cell lines.  Compared to pE2F-1h basal activity among the 
GC-rich mutants (pE2F-1hm1, pE2F-1hm2 and pE2F-1hm3) varied by > 4-fold in 
MCF-7 cells, and this was primarily due to site 2 where mutation significantly 
increased basal activity; mutation of site 3 decreased activity.  These differences 
in basal activity were only 2-fold in ZR-75 cells and this was also due to the GC-
rich site 2 suggesting that this motif may preferentially bind inhibitory factors 
such as Sp3.  Mutation of the upstream (pE2F-1hm4) or downstream (pE2F-
1hm5) CCAAT sites significantly decreased basal activity in MCF-7 cells; in 
contrast, loss of basal activity in ZR-75 cells was only observed for the former 
construct indicating important differences between contributions of the two 
CCAAT sites in determining basal activity of this region of the E2F-1 gene 
promoter.  The importance of the upstream CCAAT motif was also observed in 
hormone-responsiveness of this series of mutants (Fig. 20).  The only major 
difference in the effects of E2 on this series of constructs was that mutation of 
the upstream or downstream CCAAT elements resulted in loss of E2-
responsiveness in MCF-7 cells transfected with pE2F-1hm4 or pE2F-1hm5, 
whereas the latter (but not the former) construct was hormone-responsive in ZR-
75 cells.  The results observed in MCF-7 cells were consistent with cooperative  
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ligand (E2)-dependent formation of an ERα/Sp1/NFYA complex in which both 
cis-elements are required for transactivation (342).  However, if this complex is 
functional in ZR-75 cells, then at least the downstream (3') CCAAT site is not 
required. The results in Fig. 21 confirm that hormone-inducibility in MCF-7 cells 
transfected with pE2F-1j is lost with constructs in which the GC-rich site is 
deleted (pE2F-1jm1) or the CCAAT sites are mutated (pE2F-1jm2).  In contrast, 
both wild-type and mutant pE2F-1j constructs were hormone-responsive in ZR-
75 cells demonstrating that the CCAAT sites alone were hormone-responsive.  
Fig. 22 investigates the activity of the three GC-rich sites alone in the -169 to -
111 region of the E2F-1 gene (pE2F-1k) or in combination with the downstream 
(pE2F-1h), upstream (pE2F-1l) or both upstream/downstream (pE2F-1g) CCAAT 
motifs.  Results obtained in MCF-7 cells clearly demonstrated that hormone-
responsiveness required both the GC-rich and downstream CCAAT motifs, 
whereas the GC-rich sites alone were sufficient for E2-induced transactivation in 
ZR-75 cells. 
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Fig. 21.  Deletion and mutation analysis of E2F-1 minimal promoter region in 
MCF-7 (left) and ZR-75 (right) cells.  Constructs containing wild-type or mutant 
E2F-1 gene promoter inserts from the hormone-responsive -146 to -54 region 
were cotransfected with hER and B-galactosidase into MCF-7 or ZR-75 breast 
cancer cells, treated with DMSO (solvent control) or 10 nM E2, and luciferase 
activity was determined as described in the Materials and Methods.  Significant 
(p < 0.05) induction by E2 is indicated with an asterisk, and fold induction by E2 
is also given.  Results are expressed as means ± SE for three replicate 
determinations for each treatment group.  The 100% control values were the 
DMSO treatments in cells transfected with pE2F-1j. 
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Fig. 22.  Deletion analysis of the CCAAT sites on the E2F-1 promoter constructs 
in MCF-7 (left) and ZR-75 (right) cells.  Constructs containing wild-type or 
mutant E2F-1 gene promoter inserts from the hormone-responsive -173 to -54 
region were cotransfected with hER and β-galactosidase into MCF-7 or ZR-75 
breast cancer cells, treated with DMSO (solvent control) or 10 nM E2, and 
luciferase activity was determined as described in the Materials and Methods.  
Significant (p < 0.05) induction by E2 is indicated with an asterisk, and fold 
induction by E2 is also given.  Results are expressed as means ± SE for three 
replicate determinations for each treatment group.  The 100% control values 
were the DMSO treatments in cells transfected with pE2F-1h. 
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3.1.2 Comparative Activation of E2F-1 Promoter Constructs by Wild-type 
and Variant ERα Expression Plasmids 
Previous studies have demonstrated that E2 induced reporter gene activity 
in MCF-7 and ZR-75 cells transfected with an E2-responsive GC-rich constructs 
and wild ERα or a DBD deletion mutant (HE11) (141, 172-174, 176, 370, 371).  
This mutant was also shown to be expressed in HeLa cells by Western blot 
analysis and its binding to the estrogen response element was very weak 
compared to wildtype ERα (372, 373).  MCF-7 and ZR-75 cells were 
contransfected with E2F-1 promoter constructs, wild type ERα, and variant ERα 
mutant expression plasmids in order to determine the role of the ERα functional 
domains in E2-induced E2F-1 gene transactivation.  The results in Fig. 23 show 
that E2 induced luciferase activity in MCF-7 cells transfected with pE2F-1h or 
pE2F-1j and wild-type ERα but not HE11.  These results are consistent with the 
observation that hormone-responsiveness in MCF-7 cells requires both GC-rich 
and CCAAT motifs to form an ERα/Sp1/NFYA complex which was not activated 
in cells transfected with HE11 (342).  Thus, formation of the ERα/Sp1/NFY 
complex in MCF-7 cells does not allow direct activation of ERα/Sp1 on GC-rich 
sites alone.  Both ERα and HE11 activated pE2F-1h, pE2F-1j, and pE2F-1jm2 in 
ZR-75 cells, whereas pE2F-1jm1 containing only CCAAT sites was not induced 
by E2.  This was consistent with the hormone-responsiveness of the GC-rich 
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Fig. 23.  Comparative activation of E2F-1 constructs by wild-type and variant 
ERα constructs in MCF-7 breast cancer cells.  MCF-7 cells were cotransfected 
with constructs containing E2F-1 promoter inserts and ERα or HE11, HE15 and 
HE19 and treated with DMSO or 10 nM E2, and luciferase activity was 
determined as described in the Materials and Methods.  Significant (p < 0.05) 
induction is indicated with an asterisk, and results are expressed as means ± SD 
for three replicate determinations for each treatment group.   
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Fig. 24.  Hormonal activation of ERα mutant constructs in ZR-75 breast cancer 
cells.  ZR-75 cells were cotransfected with constructs containing E2F-1 promoter 
inserts and ERα or HE11, HE15 and HE19 and treated with DMSO or 10 nM E2, 
and luciferase activity was determined as described in the Materials and 
Methods.  Significant (p < 0.05) induction is indicated with an asterisk, and 
results are expressed as means ± SD for three replicate determinations for each 
treatment group.   
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sites alone in ZR-75 cells (141, 172-174, 176, 370, 371) and contrasted to the 
results obtained in MCF-7 cells (Fig. 24).  ERα mutants containing N-terminal 
(HE19) and C-terminal (HE15) deletions were not hormone-responsive in either 
cell line (Fig. 23 and Fig. 24). 
3.1.3 Role of NFYA in E2-induced Transactivation of E2F-1 in MCF-7 and 
ZR-75 Cells 
CCAAT sites have been shown to bind the NF-Y heterotrimer that is 
comprised of NF-YA, NF-YB, and NF-YC.  NF-YB and NF-YC are responsible 
for inducing formation of the NF-Y complex and interacting with other 
coregulators, while NF-YA is responsible for binding to the DNA CCAAT motifs 
(374, 375).  In order to confirm the role of NF-Y in E2-induced E2F-1 
transactivation, MCF-7 and ZR-75 cells were contransfected with E2F-1 
promoter constructs, ERα, and NF-Y expression plasmids.  E2 induces 
luciferase activity in MCF-7 and ZR-75 cells transfected with pE2F-1j (Figs. 25A 
and 25B), and cotransfection with NFYA, NF-YB or 4YA13 which does not 
exhibit dominant negative activity did not affect the induction response.  In 
contrast, cotransfection with the dominant negative 4YA13m29 expression 
plasmid for NFYA blocks hormone activation in MCF-7 cells and this is 
consistent with the reported hormone-dependent ERα/Sp1/NFYA-mediated 
transactivation which requires both GC-rich and CCAAT sites (342).  In contrast, 
NFYA dominant negative decreases the basal levels as well as the E2 response,  
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Fig. 25.  Effects of NFYA and transactivation.  Transfection of pE2F-1j in MCF-7 
(A) and ZR-75 (B) cells.  Transfection of pE2F-1j in MCF-7 (A) and ZR-75 (B) 
cells.  Cells were transfected with pE2F-1j and expression plasmids for hER, 
NFYA, NF-YB, NFYA + NF-YB, 4YA13m29 or 4YA13, treated with DMSO or 10 
nM E2, and luciferase activity was determined as described in the Materials and 
Methods.  Significant (p < 0.05) induction is indicated by an asterisk and results 
are expressed as means ± SD for three replicate determinations for each 
treatment group.  The 100% control values were the DMSO treatments in cells 
transfected pE2F-1j. 
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Fig. 26.  Role of NF-YA on transactivation in cells transfected with pE2F-1k and 
pE2F-1jm1.  Transfection of ZR-75 cells with pE2F-1k [A] or pE2F-1jm1 [B].  
Cells were transfected with pE2F-1k or pE2F-1jm1 and expression plasmids for 
hER, NF-YA, NF-YB, NFYA + NF-YB, 4YA13m29 or 4YA13, treated with DMSO 
or 10 nM E2, and luciferase activity was determined as described in the 
Materials and Methods.  Significant (p < 0.05) induction is indicated by an 
asterisk and results are expressed as means ± SD for three replicate 
determinations for each treatment group.  The 100% control values were the 
DMSO treatments in cells transfected pE2F-1k [A] and pE2F-1jm1 [D].    
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it does not eliminate hormone-induced transactivation in ZR-75 cells transfected 
with pE2F-1j (Fig. 25B) and this is consistent with E2-responsiveness of the GC-
rich sites alone in ZR-75 cells (Fig. 26A).  The decrease in basal levels is most 
likely due to other factors binding to the CCAAT sites and either recruiting 
corepressors and/or not allowing interaction with the basal transcription 
machninery.  The effects of NFYA, NF-YB, 4YA13 and 4YA13m29 expression 
plasmids on hormone-inducibility of pE2F-1k (Figure 26A) and pE2F-1jm1 (Fig. 
26B) were also investigated in ZR-75 cells.  The results indicate that hormone 
inducibility in cells transfected with the GC-rich construct (pE2F-1k) were 
unaffected by any of the expression plasmids, whereas the dominant negative 
NFYA expression plasmid blocked induction of pE2F-1jm1 suggesting that NFYA 
plays a key role in direct hormone activation through the CCAAT motifs in ZR-75 
cells.  
The results in Fig. 26A illustrate that dominant negative NFYA (4YA13m29) 
and NFYA expression plasmids do not affect ERα/Sp1-mediated activation of 
pE2F-1k which contains three GC-rich Sp1 binding sites.  In contrast, Farsetti 
and coworkers showed that NFYA physically interacts with ERα and inhibits 
ERα action in NIH3T3 and HepG2 cells transfected with an ERE construct.  
Moreover, this response was also observed using a form of NFYA that does not 
bind DNA (376).  Our results show that NFYA does not affect ERα/Sp1-
mediated activation of GC-rich constructs (Fig. 26A) and cotransfection with  
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Fig. 27.  Effects of NFYA on hormonal activation of pERE.  ZR-75 cells were 
transfected with pERE and different amounts (0.25  2.0 µg) of NFYA 
expression plasmid, treated with DMSO or 10 nM E2, and luciferase activity 
determined as described in the Materials and Methods.  Significant (p < 0.05) 
induction is indicated by an asterisk and results are expressed as means ± SD 
for three replicate determinations for each treatment group.  The 100% control 
values were the DMSO treatments in cells transfected pERE alone.  
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ERα activates constructs containing only CCAAT motifs (Figs. 21,24, and 26).  
Therefore, we investigated potential inhibitory interactions of NFYA on ERα in 
ZR-75 cells transfected with pERE3 (Fig. 27).  These results show that NFYA 
does not inhibit ERα-mediated transactivation in ZR-75 cells as previously 
reported in other cell lines (376) demonstrating that inhibitory NFYA-ERα 
interactions are dependent on cell context. 
3.1.4 Interaction of NFY and Sp Proteins with the E2F-1 Promoters 
 E2-treated nuclear extracts from MCF-7 and ZR-75 cells were used in 
order to confirm that Sp1 and NF-YA bound the GC-rich and CCAAT motifs, 
respectively.  Interactions of nuclear extracts from untreated and E2-treated 
MCF-7 and ZR-75 cells with [32P]-122/-54 oligonucleotide were investigated in 
gel mobility shift assays (Fig. 28).  A major protein-DNA retarded band was 
observed with both extracts in MCF-7 (lanes 2 and 3) and ZR-75 (lanes 12 and 
13) cells, and it was apparent that treatment with E2 did not affect retarded band 
intensities.  In competitive DNA-binding experiments with unlabeled -122/-54 or 
consensus NF-Y oligonucleotides, there were significant decreases in retarded 
band intensities using extracts from MCF-7 (lanes 4 and 5) or ZR-75 (lanes 14 
and 15) cells.  In contrast, competition with unlabeled consensus NF-1, Sp1 
(GC-rich) or ERE oligonucleotides had minimal effects on retarded band 
intensities (lanes 6 - 8 and 16 - 18).  NF-1 antibodies did not supershift the 
retarded band in MCF-7 (lane 10) or ZR-75 (lane 20) cells.  The results  
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Fig. 28.  Gel electrophoretic mobility shift assays for -122/-54 binding.  Nuclear 
extracts from MCF-7 or ZR-75 cells were incubated with [32P]-122/-54 and 
various unlabeled oligonucleotides or antibodies (NFYA or NF-1) and analyzed 
by gel mobility shift assays as described in the Materials and Methods.  Results 
were observed in duplicate experiments.
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Fig. 29.  Gel electrophoretic mobility shift assays for -169/-111 binding.  Nuclear 
extracts from MCF-7 or ZR-75 cells were incubated with [32P]-169/-111 and 
unlabeled nucleotides or antibodies (Sp1 or Sp3), and analyzed by gel mobility 
shift assays as described in the Materials and Methods.  Results in these assays 
were observed in duplicate experiments and specifically bound complexes and 
supershifted bands are indicated. 
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demonstrate that despite the differences in the requirements for the CCAAT 
sites for hormonal activation of constructs derived from the E2F-1 gene 
promoter, the pattern of retarded bands observed using [32P]-122/-54 was 
similar for nuclear extracts from MCF-7 or ZR-75 cells.  Moreover, the results 
also indicate that hormonal activation of CCAAT sites in ZR-75 cells was not due 
to enhanced binding of E2-induced nuclear extracts to [32P]-122/-54.  
Interaction of nuclear extracts from both cell lines with the GC-rich -169 to 
-111 region of the E2F-1 promoter were also comparable (Fig. 29).  Extracts 
from both cell lines formed multiple bands including a higher molecular weight 
complex previously associated with DNA interactions with Sp1 proteins (342) 
(bound DNA) (lanes 2, 3, 11 and 12).  Intensity of this "bound band" was 
decreased after competition with unlabeled -169/-111 and consensus Sp1 
oligonucleotides (lanes 4, 5, 13 and 14) but not after competition with unlabeled 
mutant Sp or ER oligonucleotides (lanes 6, 7, 15 and 16).  Coincubation with 
Sp1 or Sp3 antibodies gave supershifted bands with extracts from MCF-7 (lanes 
8 and 9) or ZR-75 (lanes 17 and 18) cells.  Thus, extracts from both cell lines 
form Sp1 and Sp3 complexes with the GC-rich -169 to -111 sequence from the 
E2F-1 gene promoter.  In this study and previous reports (172, 342), we did not 
observe ERα associated with Sp1 or NFYA in gel mobility shift assays, even 
though ERα physically interacts with both proteins.  However, ERα enhances 
Sp1-DNA complex formation (on-rate) and stabilized the NFYA-DNA complex 
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which was also enhanced by Sp1 (342).  The failure to observe ternary protein-
protein-DNA complexes in gel shift assays has also been reported for other 
interacting transcription factors.  For example, cyclin D1, sterol regulatory 
element binding protein, and the human T cell lymphotropic virus type 1 Tax 
protein enhance binding of ER, Sp1 and c-jun to their cognate response 
elements, respectively, but do not form a supershifted complex (377-379). 
3.1.5 Hormonal Activation of CCAAT Sites through Non-genomic 
Pathways 
Since there are no GC-rich sites or estrogen response elements present in 
the -122 to -54 region of the E2F-1 promoter, ERα-mediated transactivation is 
not induced in a genomic ERα/Sp1 or ERα/ERE dependent manner.  Therefore, 
there may be an alternative non-genomic mechanism for E2 induced E2F-1 
gene expression.  E2 has been shown to activate the cAMP/PKA pathway in 
cancer cell lines (218, 380-383) and the cAMP/PKA pathway has also been 
shown to activate the NF-Y complex (384).  The next series of experiments was 
conducted in order to determine if the E2F-1 CCAAT sites were activated 
through cAMP/PKA phosphorylation of the NF-Y complex.  The adenyl 
cyclase/cAMP inhibitor SQ22536 (400 µM) blocked E2-induced luciferase 
activity in cells transfected with pE2F-1jm1 (Fig. 30), and this inhibitor did not 
affect cell viability.  Previous studies showed that SQ22536 inhibited cAMP/PKA 
activation of a cAMP response element in ZR-75 cells (177), suggesting that this 
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pathway may be required for activation of the CCAAT sites.  This observation 
was consistent with the known activation of this pathway by E2 (175, 186, 385-
387) as well as a recent report showing that cAMP inducers activate tissue 
inhibitor of metalloproteinases-2 (TIMP-2) through CCAAT sites (384).  Results 
illustrated in Fig. 31 show that higher concentrations of E2 (> 10 nM) in the 
absence of cotransfected ERα induce luciferase activity this indicates that the 
endogenous ERα proteins are induced by E2 at higher concentration that when 
ERα in transfected. PKA expression plasmid and 8-BrcAMP also induce reporter 
gene activity in ZR-75 cells transfected with pE2F-1jm1.  Moreover, hormonal or 
PKA-induced transactivation in ZR-75 cells transfected with this construct was 
not inhibited after cotransfection with 4YA13, whereas dominant negative NFYA 
(4YA13m29) significantly blocked both induction responses (Figure 32).  These 
data are consistent with non-genomic activation of cAMP-PKA by E2 and  
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Fig. 30.  Adenyl cyclase/cAMP -dependent inhibition of CCAAT sites in ZR-75 
cells.  Cells were transfected with pE2F-1jm1 and treated with E2 (+ 
cotransfected ERα) ± 400 µM SQ22536 and luciferase activity was determined 
as described in the Materials and Methods.  Significant (p < 0.05) induction 
compared to DMSO is indicated by an asterisk and inhibition by a double 
asterisk.  Results are means ± SD of three replicate determinations for each 
treatment group.  The DMSO treatments serve as a 100% control. 
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Fig. 31.  cAMP/PKA-dependent activation of CCAAT sites or NFYA in ZR-75 
cells.  ZR-75 cells were transfected with pE2F-1jm1 and treated with 150-350 nM 
E2 alone (no cotransfected ERα), 800 µM 8-bromocAMP or a PKA expression 
plasmid (1 µg), and luciferase activity was determined as described in the 
Materials and Methods.  Significant (p < 0.05) induction (*) or inhibition (**) is 
indicated.  Results are means ± SD of three replicate determinations for each 
treatment group.  The DMSO treatments serve as a 100% control. 
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Fig. 32.  Inhibition of PKA-dependent activation of pE2F-1jm1 by dominant 
negative NFYA (∆4YA13m29).  ZR-75 cells were cotransfected with pE2F-1jm1, 
ERα, the PKA expression plasmid ( in the PKA group) and ∆4YA13 or 
∆4YA13m29 expression plasmid and treated with DMSO (DMSO and PKA), or 10 
nM E2, and luciferase activity determined as described in the Materials and 
Methods.  Significant (p < 0.05) induction (*) or inhibition (**) is indicated.  
Results are means ± SD of three replicate determinations for each treatment 
group.  The DMSO treatments serve as a 100% control.    
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subsequent downstream activation of NFYA.  We also investigated hormonal 
activation of NFYA in ZR-75 cells transfected with an expression plasmid for a 
chimeric protein containing the DNA binding domain of the yeast GAL4 protein 
fused to NFYA (full length) (pM-NFYA) and a construct containing five tandem 
GAL 4 response elements linked to a bacterial luciferase reporter gene 
(pGAL45).  E2 induced a 16-fold increase in reported gene activity which was 
inhibited in cells cotreated with E2 plus SQ22536 (Fig. 33).  These results 
confirm that hormonal activation of the cAMP/PKA pathway in ZR-75 cells 
directly activates NFYA and this is consistent with the observed hormonal 
activation of constructs containing the CCAAT sites.  Thus, hormonal activation 
of E2F-1 in ZR-75 cells involved both genomic ERα/Sp1 and non-genomic 
pathways and clearly differed from the genomic ERα/Sp1/NF-Y mechanism 
previously described in MCF-7 cells (342).
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Fig. 33. Activation of pM-NFYA.  ZR-75 cells were transfected with pM-
NFYA/pGAL45, treated with DMSO, 10 nM E2, SQ22536 or E2 + SQ22536, and 
luciferase activity determined as described in the Materials and Methods.  
Significant (p < 0.05) induction (*) or inhibition (**) is indicated.  Results are 
means ± SD of three replicate determinations for each treatment group.  The 
DMSO treatments serve as a 100% control. 
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3.2 Induction of E2F-1 Gene Expression in Breast Cancer Cells:  
Mechanisms of Inhibition by Aryl Hydrocarbon Receptor Agonists 
3.2.1 AhR/ERα Crosstalk in MCF-7 Cells Inhibits E2-induced E2F-1 Gene 
Expression 
Previous studies in this laboratory have demonstrated that E2 induces 
E2F-1 protein expression in MCF-7 and ZR-75 cells (342, 343) and TCDD has 
been shown to inhibit E2-induced expression of multiple genes in breast cancer 
cells lines (262, 291, 292, 296, 331, 332, 365, 366). Inhibitory AhR-ERα 
crosstalk was investigated in both cell lines by treatment with DMSO, E2, TCDD, 
and E2 plus TCDD and the results for MCF-7 cells are illustrated in Figs. 34-36.  
Treatment of MCF-7 cells with E2 for 6, 12, or 24 h induced a time-dependent 
increase in E2F-1 protein as previously reported in this cell line whereas 10 nM 
TCDD either did not affect (6 and 12 h) or decreased E2F-1 protein expression 
(Fig. 34).  In cells cotreated with E2 plus TCDD there was a significant decrease 
in hormone-induced  E2F-1 protein levels after cotreatment for 12 and 24 h.  
Previous studies in MCF-7 cells show that E2 also induced E2F-1 mRNA levels 
and reporter gene activity in cells transfected with constructs containing E2F-1 
gene promoter inserts that encompass the -169 to -54 promoter region (342).  
This minimal sequence binds ERα/Sp1 and NF-YA and forms a transcriptionally 
active ERα/Sp1-NF-YA complex.  The results summarized in Figs. 35 and 36  
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Fig. 34.  TCDD downregulation of E2-induced protein expression in MCF-7 cells.  
MCF-7 cells were treated with 10 nM E2, 10 nM TCDD, and E2 plus TCDD for 6, 
12, and 24 h and E2F-1 protein levels were determined as described in 
Materials and Methods.  E2F-1 protein levels in untreated cells (U) are also 
indicated. Results are are normalized to Sp1 protein levels and expressed as 
means + SE for three replicate determinations for each treatment group.  The 
relative protein value for the control group (U) set as 1 was the DMSO 
treatments.   
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Fig. 35.  Analysis of TCDD inhibition of E2 induced transactivation of E2F-1 
promoter constructs in MCF-7 cells.  Cells were transfected with constructs 
containing E2F-1 promoter inserts from the E2-responsive -728 to +77 region 
and treated with DMSO, 10 nM E2, 10 nM TCDD, and E2 plus TCDD for 48 h 
and luciferase activity was determined as described in Materials and Methods.  
Significant induction by E2 is indicated with an asterisk (*), and inhibition is 
indicated by double asterisks (**). Results for (A)-(B) are expressed as means + 
SE for three replicate determinations for each treatment group.  The 100% 
control groups were the DMSO treatments in cells transfected with pE2F-1a (A) 
and pE2F-1b (B). 
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Fig. 36.  Analysis of TCDD inhibition of E2 induced transactivation of E2F-1 
minimal promoter region in MCF-7 cells.  Cells were transfected with constructs 
containing E2F-1 promoter inserts from the E2-responsive -169 to -54 region 
and treated with DMSO, 10 nM E2, 10 nM TCDD, and E2 plus TCDD for 48 h 
and luciferase activity was determined as described in Materials and Methods.  
Significant induction by E2 is indicated with an asterisk (*), and inhibition is 
indicated by double asterisks (**). Results for (A)-(B) are expressed as means + 
SE for three replicate determinations for each treatment group.  The 100% 
control groups in (A)-(B) were the DMSO treatments in cells transfected with 
pE2F-1h (A) and pE2F-1j (B).   
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show that E2 induced transactivation in cells transfected with constructs 
containing -728 to +77 (pE2F-1a), -242 to +77 (pE2F-1b), -169 to 54 (pE2F-1h), 
and -146 to -54 (pE2F-1j) gene promoter inserts.  TCDD (10 nM) alone did not 
induce transactivation in cells transfected with these constructs; however, in 
cells cotreated with TCDD plus E2 there was significant decrease in hormone-
induced transactivation.  These results are consistent with previous studies on 
inhibitory AhR-ERα crosstalk in MCF-7 cells where the combined treatment with 
TCDD and E2 results in limiting levels of ERα which is associated, in part with 
decreased nuclear ERα and ERα/Sp1-mediated transactivation (135, 368). 
3.2.2 TCDD Inhibition of E2F-1 Gene Expression in ZR-75 Cells 
Hormone-dependent regulation of E2F-1 gene expression in ZR-75 cells 
does not depend on formation of a nuclear ERα/Sp1-NF-YA complex since both 
the upstream GC-rich and downstream NF-YA binding sites alone are E2-
responsive (343).  Genomic ERα/Sp1 activates the upstream GC-rich sites 
whereas activation of downstream NF-YA is dependent on PKA-dependent non-
genomic pathways of estrogen action.  The results in Fig. 37 demonstrate that 
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Fig. 37.  Inhibition of E2-induced E2F-1 mRNA expression by TCDD in ZR-75 
cells.  Cells were treated with DMSO, 10 nM E2, 10 nM TCDD, and E2 plus 
TCDD for 12 h, and E2F-1 and β-tubulin mRNA levels were determined as 
described in the Materials and Methods.  Results are expressed as means + SE 
for three replicate determinations for each treatment group.  Induction by E2 is 
indicated by an asterisk (*) and inhibition by TCDD is indicated by double 
asterisks (**).   
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E2 induces E2F-1 mRNA levels and TCDD alone also slightly increased E2F-1 
mRNA expression. However, in ZR-75 cells treated with TCDD plus E2 there 
was significant decrease in the hormone-induced response.  Using the same 
treatment protocol it was evident that TCDD also inhibited E2-induced E2F-1 
protein expression in ZR-75 cells within 4 hours after treatment (Fig. 38) and 
similar results were observed at longer time points (data not shown). 
A series of constructs containing GC-rich sites alone or in combination 
with the downstream NFY site were used in transient transfection studies to 
investigate inhibitory AhR-ERα crosstalk associated with genomic ERα/Sp1 
action in ZR-75 cells (Figs. 39 and 40).  The results showed that E2 induced 
activity in ZR-75 cells transfected with pE2F-1a, pE2F-1j, pE2F-1jm2 and pE2F-
1k (-169 to -111) and cotreatment with TCDD plus E2 significantly decreased 
hormone-induced activity.  These results are consistent with the data in MCF-7 
cells given in Figures 34-36 showing that inhibitory AhR-ERα crosstalk that 
involves genomic ERα/Sp1 is associated with decreased E2F-1 expression in 
the cotreatment (TCDD plus E2) group. 
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Fig. 38.  Inhibition of E2-induced E2F-1 protein expression by TCDD in ZR-75 
cells.  Cells were treated with DMSO, 10 nM E2, 10 nM TCDD, and TCDD plus 
E2 for 4 h.  E2F-1, ERα, AhR, and Sp1 levels were determined as described in 
Material and Methods.  Sp1 was used as a loading control for these 
experiments.   
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Fig. 39.  Inhibitory AhR/ER crosstalk on E2F-1 constructs in ZR-75 cells.  
ZR-75 cells were transiently transfected with E2F-1 promoter constructs 
pE2F-1h (A) and pE2F-1j (B) and treated with DMSO, E2, TCDD and 
their combination for 48 h and luciferase activity was determined as 
described in Materials and Methods.  Significant (p<0.05) induction is 
indicated with an asterisk (*) and inhibition is indicated by double 
asterisks (**), and results are expressed as means + SE for three 
replicate determinations for each treatment group. 
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Fig. 40.  Inhibitory AhR-ERα crosstalk on the E2F-1 involves genomic ERα/Sp1.  
ZR-75 cells were transiently transfected with E2F-1 promoter constructs pE2F-
1jm2 (A) and pE2F-1k (B) and treated with DMSO, E2, TCDD and their 
combination for 48 h and luciferase activity was determined as described in 
Materials and Methods.  Significant (p<0.05) induction is indicated with an 
asterisk (*), inhibition is indicated by double asterisks (**), and results are 
expressed as means + SE for three replicate determinations for each treatment 
group. 
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3.2.3 AhR-mediated Inhibition of E2-induced Protein Expression of E2F-1 
Does Not Involve Proteasome Degradation 
 Previous studies in this laboratory showed that combined treatment of 
MCF-7 or ZR-75 cells with E2 plus TCDD resulted in limiting levels of ERα 
expression which correlated with inhibition of E2-induced transactivation (using 
an ERE promoter) and Fos protein expression by TCDD (135, 368).  Moreover, 
inhibition of proteasome-dependent degradation of ERα protein by MG132 
partially reversed the inhibitory effects of TCDD.  We therefore investigated the 
role of limiting levels of ERα on inhibitory AhR-ERα crosstalk associated with 
E2F-1 in MCF-7 (Fig. 41) and ZR-75 (Fig. 42) cells.  E2 induced E2F-1 protein 
and TCDD inhibited this response in both cell lines and this was accompanied 
by decreased ERα (E2 and E2 plus TCDD treatment groups) and AhR (TCDD 
and E2 plus TCDD treatment groups) proteins as previously reported (135, 368).  
Pretreatment of the cells with the proteasome inhibitor MG132 blocked ligand-
induced downregulation of ERα and AhR.  However, inhibition of proteasomes 
also prevented hormone-induced upregulation of E2F-1 protein and levels were 
unchanged in all treatment groups.  Because of the unexpected effects of 
MG132 on hormone-induced E2F-1, this does not exclude a role TCDD limiting 
the levels of ERα available for E2-induced transactivation in inhibitory AhR-ERα 
crosstalk. 
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Fig. 41.  The role of proteasome degradation in AhR-mediated inhibition of E2-
induced E2F-1 protein expression in MCF-7 cells.  MCF-7 cells were pretreated 
with 10 µM MG132 and DMSO for 30 min and then treated with DMSO, E2, 
TCDD, and E2 plus TCDD for 6 h.  E2F-1, ERα, AhR, and Sp1 levels were 
determined as described in Material and Methods.  Sp1 was used as a loading 
control for these experiments.    
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Fig. 42.  Inhibition of proteasome degradation in AhR-mediated inhibition of E2-
induced E2F-1 protein expression in ZR-75 cells.  ZR-75 cells were pretreated 
with 10 µM MG132 and DMSO for 30 min and then treated with DMSO, E2, 
TCDD, and E2 plus TCDD for 6 h.  E2F-1, ERα, AhR, and Sp1 levels were 
determined as described in Material and Methods.  Sp1 was used as a loading 
control for these experiments.    
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3.2.4 Inhibitory AhR/ERα Crosstalk in Schneider Cells 
 SL-2 Schneider cells do not express Sp1, ERα, or the AhR, and 
functional interactions of these transcription factors were further investigated in 
this cell line transfected with pE2F-1h (Figs. 43-45).  Basal activity in cells 
transactivated with pE2F-1h alone was set at 100% and cotransfection with 250 
ng Sp1 expression plasmid caused a maximal (>350-fold) increase in activity 
(Fig. 43A).  In contrast, transfection with ERα caused a minimal (<3-fold) 
increase in luciferase activity (Fig. 43B).  Cotransfection of the AhR/Arnt 
complex caused only minimal activation of pE2F-1h (<5-fold) and in combination 
with Sp1 the effects were less than additive and TCDD did not significantly 
enhance transactivation (Figs. 43C and 44B).  This activity was not E2-
responsive since ERα does not directly interact with the E2F-1 gene promoter 
(342, 343).  In cells treated with E2 or DMSO and cotransfected with both Sp1 
and ERα expression plasmids, cotransfection with Sp1 increased basal activity 
and E2 slightly induced activity in cells transfected with 25 or 50 ng ERα 
expression plasmid and significant induction (ca 2-fold) was observed using 
higher amounts (100-1000 ng) of ERα expression plasmid (Fig. 44A).  The 
results demonstrate that in SL-2 cells ERα/Sp1 is a functional ligand-activated 
transcription factor that in turn activates GC-rich promoters.  TCDD-dependent 
inhibitory AhR-ERα crosstalk was also investigated in SL-2 cells transfected with 
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Fig. 43.  Activation of pE2F-1h by ERα, Sp1, and AhR/Arnt. Transfection of 
pE2F-1h into SL-2 cells.  Cells were transfected with pE2F-1h and pPac-Sp1 
(A), pPAC-ERα (B) and pPAC-AhR and pPAC-Arnt (C).  The cells were then 
treated with DMSO, 10 nM E2, or 10 nM TCDD for 48 h. Luciferase activity was 
determined as described in Materials and Methods.  Significant (p<0.05) 
induction is indicated by an asterisk (*) and inhibition by double asterisks (**) 
and results are expressed as means + SE for three replicate determinations for 
each treatment group. 
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Fig. 44.   Sp1 interactions with ERα and AhR.  SL-2 cells were transfected with 
pE2F-1h and titrated with 100 ng pPac-Sp1 plus pPAC-ERα (A) and 100 ng 
pPac-Sp1 plus pPAC-AhR and pPAC-Arnt (B).  The cells were then treated with 
DMSO, 10 nM E2, or 10 nM TCDD for 48 h and luciferase activity was 
determined as described in the Materials and Methods.  Significant (p<0.05) 
induction is indicated by an asterisk (*) and results are expressed as means + 
SE for three replicate determinations for each treatment group. 
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Fig. 45.  TCDD-dependent inhibition of hormone-induced pE2F-1h in SL-2 
cells.  SL-2 cells were transfected with pE2F-1h and titrated with 100 ng 
pPAC-Sp1, 250 ng pPAC-ERα, plus different amounts of pPAC-AhR and 
pPAC-Arnt.  The cells were then treated with DMSO, 10 nM E2, 10 nM 
TCDD and their combination for 48 h and luciferase activity was 
determined as described in Materials and Methods.  Significant (p<0.05) 
induction is indicated by an asterisk (*), inhibition is indicated by double 
asterisks (**) and the results are expressed as means + SE for three 
replicate determinations for each treatment group. 
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ERα, Sp1, and AhR/Arnt expression plasmids, pE2F-1h and treated with DMSO, 
TCDD, E2 or their combination (Fig. 45).  E2-responsiveness was observed in 
cells treated with E2 and transfected with ERα and Sp1 and after cotransfection 
with 50 ng AhR/Arnt the E2-induced response for the E2 group was decreased 
and cotreatment with TCDD further inhibited this response.  Thus inhibitory AhR-
ERα crosstalk could also be observed in SL-2 cells transfected with pE2F-1h 
and this was comparable to results obtained for the same constructs in ZR-75 
cells (Figs. 39 and 40).  In contrast, cotransfection with increasing amounts of 
AhR/Arnt did not significantly affect transactivation in cells treated TCDD alone 
or TCDD plus E2.  However, E2-induced transactivation was slightly decreased 
and this was accompanied by increased luciferase activity in DMSO (control) 
treated cells.  Even though E2-responsiveness is lost after transfection with 
higher amounts of AhR/Arnt (100-500 ng), luciferase activity was significantly 
decreased in the TCDD plus E2 group compared to the E2-treated group in SL-2 
cells transfected with 50, 100, 250, or 500 µg AhR/Arnt.  These results are 
consistent with the activity of AhR/Arnt acting as a ligand-dependent repressor 
of ERα/Sp1.  
  
 
141
3.2.5 TCDD Inhibition of E2F-1 Gene Expression through the cAMP/PKA 
Pathway 
 E2-dependent induction of E2F-1 in ZR-75 cells results in activation of 
NF-YA through non-genomic pathways associated with activation cAMP/PKA.  A 
recent study showed that TCDD induced the transcriptional repressor HES-1 in 
T47D breast cancer cells and HES-1 inhibits E2-induced E2F-1 through direct 
interactions with a HES-1 response element in the E2F-1 promoter (388, 389). In 
order to determine if HES-1 played a role in inhibitory AhR-ERα cross talk, ZR-
75 cells were transfected with pE2F-1d which contains two CCAAT sites, the 
HES-1 motif and two downstream E2F sites within the -122 to +77 region of the 
E2F-1 promoter.  E2 induced luciferase activity of pE2F-1d(Fig. 46A).  Only 
minimal induction of HES-1 by TCDD was observed in ZR-75 cells (data not 
shown) and in cells transfected with pE2F-1j, TCDD significantly inhibited 
hormone-induced transactivation (Fig. 46B).  The -122 to -54 E2F-1 promoter 
sequence which is contained in pE2F-1j does not contain the HES-1 response 
element (-41 to -36) indicating that inhibitory AhR-ERα crosstalk is HES-1-
independent and associated with interaction with the cAMP/PKA signaling 
pathway.  Western blot analysis of whole cell lysates from ZR-75 cells treated 
with DMSO, E2, TCDD or TCDD plus E2 for 2 h in order to investigate the role of 
TCDD in E2-induced PKA phosphorylation.  TCDD inhibited hormone-induced 
E2F-1 protein expression and PKA phosphorylation whereas PKA and Sp1  
  
 
142
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 46.  AhR-dependent inhibition of E2F-1 transactivation is HES-1 
independent in ZR-75 cells.  Cells were transfected with pE2F-1d and pE2F-1j 
and treated with DMSO, 10 nM E2, 10 nM TCDD and their combination for 48 h 
and luciferase activity was determined as described in Materials and Methods.  
The results are expressed as means + SE of three replicate determinants for 
each treatment group and significant (p<0.05) induction is indicated by an 
asterisk (*) and inhibition by double asterisks (**).    
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Fig. 47.  Inhibition of hormone-induced E2F-1 protein and PKA phosphorylation 
by TCDD.  Cells were treated for 2 to 4 h with DMSO, E2, TCDD and TCDD plus 
E2 and E2F-1, phospho-PKA, PKA, and Sp1 protein levels were determined as 
described in Materials and Methods.   
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(loading control) proteins were unchanged in all treatment groups (Fig. 47). PKA 
activity was also inhibited by TCDD in cells treated with 8-bromo-cAMP or 
transfected with a constitutively- active PKA expression plasmid (Fig. 48).  
Previous studies have demonstrated that like TCDD, the adenyl cyclase inhibitor 
SQ22356 also blocked hormone-induced transactivation in ZR-75 cells 
transfected with pE2F-1j and we therefore compared the activity of TCDD and 
SQ22536 as inhibitors of cAMP production in ZR-75 cells (Table 4).  cAMP 
levels varied from 1.5 - 17 pmol/mg and after treatment with E2 for 30, 60, or 
120 min cAMP levels significantly increased to 6.0 + 0.1, 4.8 + 0.2 and 3.6 + 0.5 
pmol/mg respectively.  TCDD alone had no effect on the cAMP levels.  However, 
in cells treated with TCDD plus E2, hormone-induced cAMP was completely 
suppressed at the three time points.  Moreover, similar inhibitory effects were 
observed for SQ22536 suggesting that AhR-mediated inhibition of the hormone-
induced cAMP/PKA pathway in ZR-75 cells is linked to direct inhibition of adenyl 
cyclase activity and this inhibition subsequently affects E2F-1 transactivation 
through NF-YA (Fig. 49).  This represents the first example of AhR-dependent 
inhibition of non-genomic pathways of ER action and demonstrates that 
inhibitory AhR-ERα crosstalk associated with E2F-1 involves inhibition of both 
genomic and non-genomic pathways of estrogen action. 
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Fig. 48.  Inhibitory AhR/ERα effects on cAMP/PKA transactivation of the pE2F-
1jm1.  (A).  Inhibition of 8 Br-cAMP induced E2F-1 transactivation by TCDD.  
Cells were transfected with pE2F-1g and treated with DMSO, 1µM 8 Br-cAMP, 
TCDD, and TCDD plus 8 Br-cAMP for 48 hrs.  (B) ZR-75 cells were co-
transfected with a PKA expression plasmid and treated with DMSO and TCDD. 
Luciferase activity was determined as described in Materials and Methods.  The 
results are expressed as means + SE of three replicate determinants for each 
treatment group and significant (p<0.05) induction is indicated by an asterisk (*) 
and inhibition by double asterisks (**).      
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Table 4.  cAMP  enzyme immunoassay (EIA) ZR-75 cellsa. 
Treatment 
                                                                        cAMP levels (pmol/mg protein) 
 
 30 min 60 min 120 min 
control 1.7 +0.1 1.6 + 0.1 1.5 + 0.1 
E2 6.6 + 0.1 4.8 + 0.2 3.6 + 0.5 
TCDD 1.7 +0.4 1.8 + 0.3 1.8 + 0.2 
E2 + TCDD 1.8 + 0.2 1.6 + 0.4 2.0 + 0.6 
SQ22536 1.8 +0.1 1.8 + 0.5 1.9 + 0.1 
E2 + SQ22536 2.0 + 0.7 1.9 + 0.1 1.5 + 0.5 
    
aZR-75 cells were treated for different times as cAMP levels were determined as 
described in the Materials and Methods.  Significant (p< 0.05) induction by E2 
and inhibition by TCDD or SQ22536 (**) are indicated. 
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Fig. 49.  Inhibition of hormone-induced activation of pM-NFYA by TCDD.  
ZR-75 cells were transfected with pM-NFYA/pGal45 and treated with 
DMSO, 10 nM E2, 10 nM TCDD, TCDD plus E2, 400 µM SQ22536, and 
E2 plus SQ22536 and luciferase activity was determined as described in 
Materials and Methods.  Results are means + SE of three replicate 
determinants for each treatment group and significant (p<0.05) induction 
is indicated by an asterisk (*) and inhibition by double asterisks (**).    
0
100
200
300
400
500
600
700
800
DMSO E2 TCDD E2+TCDD SQ E2+SQ
%
 c
on
tr
ol
**
**
**
**
*
%
 c
on
tr
ol
pm-NFYA/pGAL45 
  
 
148
CHAPTER IV 
 
DISCUSSION AND CONCLUSIONS 
 
4.1 Cell Context-dependent Differences in the Hormonal Activation of E2F-
1 Gene Expression 
E2F transcription factors play a critical role in cell growth and are key 
regulators of G1→S phase progression of the cell cycle (349-352).  E2F plays a 
paradoxical role in carcinogenesis and exhibits characteristics consistent with 
oncogenic and tumor suppressor activity (348-351).  E2F-1-/- and E2F-1+/- mice 
are viable and, surprisingly, exhibit age-dependent hyperplastic and neoplastic 
responses suggesting some tumor suppressor activity (390, 391).  E2F-1 also 
exhibits oncogenic activity and E2F-1 enhances formation of some tumors in 
mice lacking a functional Rb1 allele (392, 393).    Using a transgenic murine 
model in which overexpression of E2F-1 is controlled by the keratin 5 promoter, 
it was reported that E2F-1 alone or in combination with other factors enhanced 
development of skin carcinomas and tumors in many other tissues (394-396).  In 
contrast, these transgenic mice were resistant to development of skin tumors in 
a two-stage initiation-promotion model (396).  Thus, E2F-1 overexpression can 
result in both oncogenic and tumor suppressive activity in the same tissue. 
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 MCF-7 and ZR-75 are ER-positive breast cancer cell lines which are 
extensively used as models for investigating cell context-dependent differences 
in the molecular mechanisms of hormone-induced transactivation.  For example, 
in ZR-75 cells E2 induces transactivation in cells transfected with constructs 
containing GC-rich proximal promoter inserts from the VEGF gene, whereas E2 
decreases activity in MCF-7 and HEC1A cells (260) transfected with the same 
constructs.  Previous studies have reported that E2 induces E2F-1 mRNA levels 
in MCF-7 cells (342), and similar results were observed in ZR-75 cells (Fig. 19).  
Deletion and mutation analysis of a series of constructs containing the -169/-173 
to -54 region of the E2F-1 promoter clearly demonstrate cell context-dependent 
differences in hormonal activation of these constructs in MCF-7 vs. ZR-75 cells 
(Figs. 20-22).  In the former cell line, one or more of the GC-rich motifs (-169 to -
111) and both CCAAT elements (-122 to -54) are required for ERα/Sp1/NFYA 
interactions on this promoter (Fig. 50).  This same complex may play some role 
in hormone-induced transactivation in ZR-75 cells; however, the results clearly 
demonstrate that the GC-rich sites alone (pE2F-1k) or the CCAAT sites alone 
(pE2F-1jm1) are sufficient for hormone activation.  Gel mobility shift assays 
exhibit similar patterns of Sp1 and NFYA binding to the proximal region of the 
E2F-1 gene promoter in MCF-7 and ZR-75 cells (Figs. 23-27); however, there 
were clear differences in transactivation by ERα mutants in the two cell lines 
(Figs. 23 and 24).  In ZR-75 cells, hormone-induced transactivation was  
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Fig. 50.  The ERα/Sp1/NFY complex in MCF-7 cells.  The NFY proteins bind to 
the CCAAT motifs and Sp1 binds to the GC-rich motifs.  Upon E2 treatment, 
ERα hetorodimerizes and forms an ERα/Sp1/NFY complex and interacts with 
coactivators that allow interactions with the basal transcription machinery to 
activate transcription of the E2F-1 gene in MCF-7 cells. 
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observed in cells transfected with the DBD-mutant HE11 and constructs 
containing GC-rich sites and mutated CCAAT sites (-146/-54) alone or in 
combination with CCAAT motifs (Fig. 24).  These results are consistent with 
activation of GC-rich constructs by ERα/Sp1 observed for other E2-responsive 
gene promoters in ER-positive breast cancer cells (141, 172-176, 370, 371).  In 
contrast, transfection with HE11 does not activate pE2F-1h or pE2F-1j (Fig. 23) 
in MCF-7 cells, and this differentiates between the transcriptionally-active 
ERα/Sp1/NFYA complex formed in MCF-7 cells (Fig. 50) in which the GC-rich 
site alone is not hormone-responsive (Fig. 22), whereas in ZR-75 cells, both GC-
rich and CCAAT sites alone are hormone-responsive (Figs. 21 and 22). 
ERα/Sp1-mediated activation of GC-rich motifs has been characterized in 
several E2-responsive gene promoters (141, 172-176, 370, 371), and hormone-
dependent activation of constructs containing only the GC-rich sequences (i.e. 
pE2F-1jm2 and pE2F-1k) in ZR-75 cells is not surprising.  The failure to activate 
the GC-rich constructs from the E2F-1 gene promoter in MCF-7 cells (Figs. 20-
22) suggests that the cell context-dependent differences between ZR-75 and 
MCF-7 cells must be related in part, to specific regions within this GC-rich 
promoter.  Although the E2F-1-derived GC-rich constructs alone were not 
hormone-responsive in MCF-7 cells, there are many other examples of GC-rich 
promoter constructs that are induced by E2.  For example, the bcl-2 gene has 
two regions that are important for transactivation (175).  The upstream region 
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contains to GC-rich sequences that were shown to interact with Sp1 in gel shift 
mobility assays and in vitro footprinting.  Transcriptional activation of bcl-2 
promoter constructs containing GC-rich sites was induced by E2 through 
ERα/Sp1 interactions (175).  Several other genes that are induced by E2 in 
MCF-7 cells are activated through one or more GC-rich sites in their regulatory 
regions and these include the cathepsin D (365, 367), c-fos (173), adenosine 
deaminase (174, 210), cad (178), and retinoic acid receptor alpha 1 (370) genes 
(Fig. 51). However, there are several other genes that contain one or more 
proximal GC-rich promoter elements that also bind Sp1 but are not hormone-
responsive in transactivation assays, and some of these include ornithine 
decarboxylase (218), lactate dehydrogenase-A (219), and p53 (217) genes (Fig. 
51). Studies in this laboratory have also demonstrated ligand-dependent 
differences in activation of GC-rich constructs in MCF-7 and ZR-75 cells (141, 
234, 262).  For example, E2 and antiestrogens activate a construct (pSp13) 
containing three tandem consensus GC-rich sites where as GC-rich promoters 
from several E2-responsive genes are activated by E2 but not antiestrogens. ICI 
182,780 and 4-OH-tamoxifen both induced transactivation of pSp13 in MCF-7 
and ZR-75 cells yet they both inhibited E2-induced transactivation of E2F-1 
promoter constructs containing the upstream GC-rich motifs with or without the 
downstream CCAAT motifs (Figs. 52 and 53 unpublished data, Ngwenya 2004).  
Current studies are focused on identifying motifs within the GC-rich region of the 
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Fig. 51.  GC-rich gene promoter constructs that are ERα/Sp1-dependent or 
independent in MCF-7 cells. (A) Promoter constructs of genes that have at least 
one GC-rich site and undergo ERα/Sp1-mediated transactivation in MCF-7 cells.  
(B)  Promoter constructs of genes that have at least one GC-rich site but are not 
transactivated in an ERα/Sp1-dependent manner. 
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Fig. 52.  Comparative analysis of ICI 182,780 treatment on transactivation 
in MCF-7 cells.  MCF-7 cells were transfected with pE2f-1h or pSp13 and 
treated with DMSO, E2 , 10 nM ICI, and E2 plus ICI.  Luciferase activity 
was determined as described in Materials and Methods.  Significant 
(p<0.05) induction is indicated by an asterisk (*), inhibition is indicated by 
double asterisks (**) and the results are expressed as means + SE for 
three replicate determinations for each treatment group. 
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Fig. 53.  The effects of  ICI 182,780  and 4-OH-tamoxifen on 
transactivation of GC-rich promoters in ZR-75 cells.  ZR-75 cells were 
transfected with pE2F-1k or pSp13 and treated with DMSO, E2, ICI, and 
E2 plus ICI or tamoxifen and E2 plus tamoxifen.  Luciferase activity was 
determined as described in Materials and Methods.  Significant (p<0.05) 
induction is indicated by an asterisk (*), inhibition is indicated by double 
asterisks (**) and the results are expressed as means + SE for three 
replicate determinations for each treatment group. 
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 E2F-1 promoter that determine cell context-dependent differences in their 
hormone-responsiveness. 
Dominant negative NFYA (4YA13m29) interacts with NFYB but the 
resulting complex does not bind CCAAT sites (397, 398).  In MCF-7 cells 
transfected with pE2F-1j, dominant negative NFYA inhibited E2-induced 
transactivation, whereas E2-inducibility is decreased but not lost in ZR-75 cells 
(Fig. 25).  Overexpression of 4YA13m29 in ZR-75 cells also blocked activation 
of a construct containing the CCAAT sites (pE2F-1jm1) but not the GC-rich sites 
(pE2F-1k) (Fig. 26) confirming the hormone-inducibility of the CCAAT motifs in 
this cell line.  Transfection with NFYA or ∆4YA13 (a long form of NFYA) did not 
affect hormone-responsiveness.  Interactions between NFYA and ERα have 
previously been reported on the human coagulation factor XII promoter where 
NFYA inhibits ERα-mediated transactivation from motifs which contain an 
overlapping CCAAT/nonconsensus ERE site (376).  NFYA also inhibits 
hormone-induced transactivation in NIH3T3 and human HepG2 cells transfected 
with ERα and a construct containing a consensus ERE promoter (376).  In 
contrast, our results in ZR-75 cells show that NFYA does not inhibit ERα/Sp1 
action in cells transfected with a GC-rich construct (pE2F-1k; Fig. 24) nor does 
NFYA inhibit hormone-induced transactivation from an ERE promoter in ZR-75 
cells (Fig. 27).  Thus, inhibitory NFYA-ERα interactions are also cell context-
dependent.  
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 The unique hormone-dependent activation of constructs containing 
CCAAT motifs that bind NFYA was not accompanied by increased binding to 
these sites as determined in gel mobility shift assays (Fig. 28).  A recent report 
showed that cAMP induced transactivation of human tissue inhibitor of 
metalloproteinases-2 through activation of NFYA bound to  a CCAAT site (384).  
E2 activates the cAMP/PKA pathway in several cell lines including breast cancer 
cells (175, 186, 385-387).  Studies using the bcl-2 and cyclin D1 genes revealed 
that E2 activates the cAMP/PKA pathway in MCF-7 and ZR-75 cells (Fig. 54) 
(175, 177). Therefore we further investigated the role of this non-genomic 
pathway in E2-dependent activation of an E2F-1-derived construct containing 
CCAAT motifs (pE2F-1jm1) in ZR-75 cells.  The results in Figure 30 show that 
hormonal activation of pE2F-1jm1 is inhibited by the adenyl cyclase inhibitor 
SQ22536; E2 (in the absence of cotransfected ERα), 8-bromo-cAMP and 
constitutively active PKA also activate pE2F-1jm1 (Fig. 29), and dominant 
negative NFYA inhibits E2 and PKA induction of the same construct (Fig. 32).  
Moreover, E2-dependent activation of the GAL4-NFYA fusion protein is also 
inhibited by SQ22536 in ZR-75 cells, and this was consistent with comparable 
inhibition of pE2F-1jm1.   This represents a novel non-genomic pathway for 
activation of NFYA by E2 and is consistent with reports in other cell lines 
showing cAMP/PKA-dependent activation of NFYA as illustrated in Fig. 54 (384).  
The precise mechanisms of extranuclear ERα interactions with adenyl cyclase  
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Fig. 54.  cAMP/PKA activation of NFY proteins in ZR-75 cells.  E2 treatment 
activates adenyl cyclase, an enzyme that catalyzes the conversion of ATP to 
cAMP.  Production of cAMP causes the dissociation of inactive PKA into its 
regulatory and active catalytic subunits.  The catalytic subunits of PKA 
translocate into the nucleus and phosphorylate transcription factors such as 
NFY.  AC-Adenyl cyclase, R-regulatory subunit of PKA, C-catalytic subunit of 
PKA, P-phosphorylation. 
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are unknown. However, activation of this enzyme results in enhanced cAMP 
production and release of the active catalytic form of PKA.  The precise site(s) of  
phosphorylation on NFY are unknown.  However, NFYB, a regulatory subunit of 
the NFY complex, was found to be the target site for cAMP signaling on the 
ferritin promoter (399). 
 Non-genomic pathways activated by E2 have been characterized in 
multiple cell lines including breast cancer cells (189, 190, 205, 400, 401).  The 
mechanisms associated with these pathways are complex and may be 
dependent on several factors including cell context and ER-subtype (192, 402).  
Results of this study clearly demonstrate that cell context (MCF-7 vs. ZR-75) is 
an important factor in hormonal regulation of E2F-1 gene expression, and in ZR-
75 cells, a combination of both genomic (ERα/Sp1) and non-genomic 
(cAMP/PKA) signaling is required.  Interestingly, a combination of these 
pathways has also been reported for induction of c-fos, cyclin D1 and bcl-2 in 
MCF-7 or ZR-75 cells (173, 215, 259).  These gene promoters all contain E2-
responsive GC-rich motifs as well as cAMP response elements (bcl-2 and cyclin 
D1) (Fig. 55) or a serum response element (c-fos) (Fig. 56) activated through 
mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3-
K) (215, 259, 403).  Since inhibitors of MAPK and PI3-K pathways block E2-
induced proliferation of MCF-7 cells (215, 259, 403), the identification of 
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Fig. 55.  Bcl-2 (MCF-7) and cyclin D1 (ZR-75) non-genomic pathways.  Bcl-2 
and cyclin D1 promoters contain CREs in their promoter regions that are bound 
by CREB.  Upon E2 treatment, adenyl cyclase is activated and catalyzes the 
conversion of ATP to cAMP.  cAMP activity induces the dissociation of inactive 
PKA into its regulatory and active catalytic subunits.  The catalytic subunts 
translocate into the nucleus where they activate CREB by phosphorylation.  
CRE  cAMP response element, CREB  CRE binding protein (175, 177).
E2
ERAC
ATP cAMP
R R
+
R R
c c
c
P
P
c
P
P
CRE
CREB
cytoplasm
nucleus
PKA (inactive)
PKA (active)
E2
  
 
161
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 56.  Estrogen and growth factor activation of Elk-1 and a serum response 
element (SRE) in the c-fos gene promoter.  The c-fos gene promoter contains an 
SRE that is bound by Elk-1 and SRF.  E2 treatment activates the MAPK 
pathway that eventually phosphorylates Elk-1 thereby activating transcription. 
GFR  growth factor receptor, SRF  serum response factor. 
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downstream E2-responsive gene targets such as E2F-1, cyclin D1, c-fos and 
bcl-2 is consistent with the contributions of non-genomic pathways of estrogen 
action.  Current studies are investigating the mechanisms of non-classical 
genomic and non-genomic pathways on growth regulatory genes in breast 
cancer cells and determining cellular factors that influence cell context-
dependent mechanistic differences, even among ER-positive breast cancer cell 
lines.  The possibilities include the recruitment of corepressors that may inhibtit 
transactivation in one cell line whereas coactivators may be recruited to induce 
transactivation in another cell line.  
4.2 Inhibition of E2-induced Expression of E2F-1 by TCDD  
 E2F-1 and related proteins play an important role in cell proliferation and 
phosphorylation-dependent dissociation of the E2F-1-Rb complex results in 
release of E2F-1 and subsequent activation of E2F-1 dependent genes (352-
354, 404).  The oncogenic potential of E2F-1 is associated with overexpression 
of E2F-1-regulated genes and their enhancement of cell growth (Fig. 57) (352-
354, 394-396, 404).  In contrast, E2F-1 also exhibits tumor suppressor activity 
and E2F-1-/-/E2F-1+/+ mice show early development of hyperplastic and 
neoplastic responses (390, 391).  Overexpression of E2F-1 in some cancer cell 
lines results in activation of cell death pathways suggesting a possible 
mechanism for E2F-1-dependent tumor growth inhibition (Fig. 57) (405).   
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Fig. 57.  E2F-1 as an oncogene and a tumor suppressor.  E2F-1 has the ability 
to be an oncogen as well as a tumor suppressor.  When DNA is damaged, there 
is an overexpression of E2F-1 regulated genes that are either involved in cell 
proliferation or apoptosis and DNA repair.  If genes involved in cell proliferation 
are overexpressed, E2F-1 promotes oncogenesis and if apoptosis genes are 
overexpressed, E2F-1 activates the cell death pathways. 
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 E2-dependent regulation of E2F-1 in MCF-7 and ZR-75 cells is primarily 
associated with increased proliferation.  Previous studies showed that E2-
responsiveness in both cell lines was associated with the proximal GC-rich (-169 
to -11) and CCAAT (-111 to -54) elements; however, as indicated in the previous 
section there were significant differences in mechanisms of hormone-dependent 
activation (342, 343).  ERα/Sp1-dependent activation through interactions with 
the GC-rich elements was observed in both cell lines; however, in MCF-7 cells 
E2-induced transactivation required cooperative interactions with downstream 
NF-YA transcription factors whereas in ZR-75 cells both GC-rich and CCAAT 
sites were independently activated by E2.  Estrogen-responsive genes and 
tumors are inhibited by antiestrogens such as tamoxifen and ICI 182,780 and 
these same compounds are also used for treatment of breast cancer in women.  
Other compounds such as retinoids (406, 407), PPARγ (408) and vitamin D 
receptor agonists (409-411) also inhibit mammary tumor growth, and research in 
our laboratory has observed inhibitory AhR-ERα crosstalk which includes 
inhibition of mammary tumor growth (272, 273, 412).  The mechanisms of these 
interactions between the AhR and ERα signaling pathways are complex and 
involve interactions of the AhR with specific promoter regions (iDREs) of some 
E2-responsive genes (262), proteasome-dependent downregulation of ERα 
(368), and induction of inhibitory factors such as HES-1 (388, 389). The 
mechanisms of inhibitory AhR-ERα cross-talk using the E2F-1 gene as a model 
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were investigated in MCF-7 and ZR-75 breast cancer cells to take advantage of 
their subtle differences in hormonal regulation of E2F-1.   
 TCDD inhibited E2-induced E2F-1 mRNA and/or protein levels in MCF-7 
(Fig. 34) and ZR-75 (Figs. 37 and 38) cells, and similar interactions were 
observed in cells transfected with pE2F-1 constructs (Figs. 35,36,39 and 40).  
Previous studies have demonstrated that direct interactions of the AhR complex 
with specific iDREs can inhibit E2-induced expression of cathepsin D, c-fos, pS2 
and heat shock protein 27, and this is associated with AhR squelching or 
disrupting of a functional ERα or ERα-protein complex (32-37).  The proximal 
region of the E2F-1 gene promoter does not contain a iDRE motif (GCGTG), and 
the decreased transactivation in both cell lines transfected with various E2F-1 
constructs must be due to other mechanisms.  It was not possible to determine 
the importance of limiting levels of ERα expressed in cells after treatment with 
TCDD plus E2 since the proteasome inhibitor MG132 alone prevented hormone-
dependent activation of E2F-1 (Figs. 41 and 42).  It is possible that levels of 
ERα in these cells after treatment with TCDD plus E2 may contribute to the 
antiestrogenic effects of TCDD as previously reported (135, 368).  We also 
investigated these responses in SL-2 cells which do not express ERα, Sp1, or 
AhR/Arnt.  In cells transfected with pE2F-1h, ERα and Sp1 expression plasmids 
(Fig. 44A) E2 significantly induced transactivation.  These data are consistent 
with a previous report showing hormone-induced transactivation in SL-2 cells 
  
 
166
transfected with ERα and Sp1 expression plasmids and constructs containing 
GC-rich promoter inserts from the DNA polymerase α, thymidylate synthase, 
TGFα, and bcl-2 genes (10,53-55).  In SL-2 cells transfected with pE2F-1h and 
AhR/Arnt expression plasmids, TCDD did not affect luciferase activity (Figs. 43C 
and 44B).  However, in cells cotransfected with ERα (250 ng)/Sp1(100 ng) (E2-
responsive, Fig. 44A) and the lowest amount of AhR/Arnt (50 ng), TCDD 
significantly inhibited E2-induced luciferase activity (Fig. 45) and the results were 
comparable to inhibitory responses observed in MCF-7 (Fig. 36A) and ZR-75 
(Figure 39A) cells transfected with the same constructs.  Increasing amounts of 
the AhR complex (unliganded) (100-500 ng) slightly decreased hormone-
induced transactivation due to parallel increase in basal (DMSO) activity (250 
and 500 ng) (Fig. 44A).  Luciferase activity in SL-2 cells treated with TCDD plus 
E2 was significantly lower than activity in cells treated with E2 alone and 
transfected with 50, 100, 250, or 500 ng AhR/Arnt.  The results suggest that the 
liganded AhR complex represses ERα/Sp1 and this is consistent with previous 
reports showing that AhR/Arnt interacts directly with ERα and Sp1 proteins (339, 
341).  The model shown in Fig. 58 shows that AhR/Arnt acts as a ligand-induced 
corepressor that interacts with ERα/Sp1 and prevents subsequent recruitment of 
coactivators and basal transcriptional machinery. 
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Fig. 58.  AhR/Arnt-mediated inhibition of ERα/Sp1 transactivation.  (A) ERα/Sp1-
mediated transactivation is a result of the recruitment of coactivators that interact 
with the ERα/Sp1 complex and the basal transcription machinery.  (B) AhR/Arnt 
interaction with Sp1 inhibits ERα-mediated responses by preventing ERα from 
interacting with Sp1 and thereby not allowing interaction between the 
coactivators and the basal transcription machinery (233, 413). 
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 The studies in MCF-7, ZR-75 and SL-2 cells demonstrate that AhR 
agonists inhibit genomic ERα/Sp1-mediated transactivation.  However, in ZR-75 
cells TCDD also inhibits E2-dependent activation of pE2F-1d and pE2F-1j.  
These constructs contain two hormone responsive CCAAT sites, which are 
activated through non-genomic cAMP/PKA pathways (343).  It has been recently 
reported that TCDD induces the transcriptional inhibitor HES-1 in T47D cells 
(388) and the E2F-1 promoter contains a HES-1 response element at -41 to -36 
(CACGAG) (389) and the involvement of HES-1 could explain the inhibitory 
effects of TCDD on constructs containing both CCAAT an HES-1 sites.  
However TCDD inhibits E2-dependent transactivation in cells transfected with 
pE2F-1d and pE2F1j.  The latter construct does not contain that HES-1 
response element suggesting the HES-1 activation is not involved in the 
inhibitory response induced by TCDD.  Since TCDD also inhibits E2-dependent 
phosphorylation of PKA (Fig. 47), we further investigated E2/TCDD interactions 
on regulation of adenyl cyclase activity (Table 4).  These results demonstrate 
that induction of cAMP by E2 was inhibited by both TCDD and the specific 
adenyl cyclase inhibitor SQ22536.  Previous studies in human granulosa cells 
showed that TCDD also decreased PKA activity (414) and in this study we have 
also observed inhibition of PKA activity by TCDD in cells treated with 8-bromo-
cAMP or transfected with a constitutively-active PKA expression plasmid (Fig. 
48).  Thus, TCDD can inhibit both adenyl cyclase activity and PKA-dependent 
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phosphorylation, and this results in the failure to activate NFY proteins in the 
proximal regions (-122 to -54) of the E2F-1 promoter (Fig. 59).  These results 
demonstrate that TCDD inhibits E2-dependent activation of both non-genomic 
and genomic pathways of ER activation associated with the E2F-1 gene/gene 
promoter.  The effects are similar to those observed for some antiestrogens 
such as ICI 182,780 which also inhibits genomic and non-genomic pathways of 
E2 action and like TCDD also induces proteasome-dependent degradation of 
ERα (190, 415).  Ohtake and coworkers (340) reported that Ah receptor 
agonists such as TCDD and 3-methylcholanthrene exhibited estrogenic activity 
through AhR-ERα interactions where ERα acts as a DNA bound transcription 
factor and the liganded AhR exhibits coactivator activity.  In contrast, results of 
this study suggest that the ligand bound AhR complex corepresses ERα/Sp1.  
This type of interaction has also not been observed in other studies in vitro and 
in vivo (135, 262, 291, 292, 296, 331, 332, 334, 366-368) and is currently being 
reexamined in this laboratory.  Current studies are also investigating 
mechanisms of AhR-mediated inhibition of other E2-responsive genes and 
development of selective AhR modulators for treatment of breast cancer.  
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Fig. 59.  Inhibition of E2-dependent activation of cAMP/PKA by TCDD and the 
E2F-1 gene promoter in ZR-75 cells.  E2 induces cAMP/PKA activation of the 
CCAAT motifs on the E2F-1 promoter.  TCDD treatment inhibits adenyl cyclase 
activation and subsequently prevents PKA and NFY phosphorylation thereby 
inhibiting E2-mediated responses. 
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